Open-label, Single-arm, Phase II Study, Evaluating Safety and Efficacy of INCB054828 (Pemigatinib) as Adjuvant Therapy for Molecularly-selected, High-risk Patients With Urothelial Carcinoma Who Have Received Radical Surgery
Phase: PHASE2
Conditions: Urothelial Cancer
Sponsor: European Association of Urology Research Foundation

EAU RF protocol  2018-02 
                                                                                                                                                          
Adjuvant Pemigatinib in surgically treated high-risk UC  
 
 
 
 
 
 
 
 
Final version 2.1, October 4th, 2021 
 
 
 
Open-label, single-arm, Phase II study, evaluating 
safety and efficacy of INCB054828 (Pemigatinib) as 
adjuvant therapy for molecularly-selected, high-risk 
patients with urothelial carcinoma who have received 
radical surgery.  
A European Association of Urology Research 
Foundation Phase II Clinical Trial 
 
   
 
 
 
 
 
CONFIDENTIAL 
 
 
 
Final version 2.1: 
 
 
October 4th, 2021 
Sponsor and Central Study-   
EAU Research Foundation 
Management:  
 
 
Mr. E.N. van Kleffensstraat 5 
 
 
 
 
 
NL 6842 CV Arnhem 
 
 
 
 
 
PO Box 30016 
 
 
 
 
 
6803 AA Arnhem 
 
 
 
 
 
The Netherlands 
 
 
 
 
 
Tel: + 31 26 389 0677 
 
 
 
 
 
Fax +31 26 389 0679 
 
 
 
 
 
E-mail: researchfoundation@uroweb.org 
 
 
 
 
 
www.uroweb.org 
 
EAU RF number:  
 
 
2018 - 02 
 
Eudract Number: 
 
 
2019-001833-14 
 
Acronym: 
 
 
 
PEGASUS 
 
Principal Investigator:  
 
Andrea Necchi, MD 
IRCCS San Raffaele Hospital and Scientific Institute 
Via Olgettina 60,   
20132 Milano, Italy; 
 
 
 
 
 
 
 
 
 
 
Telephone : +39 (02) 23902402 
 
 
 
 
 
Fax : +39 (02) 76010185 
 
 
 
 
 
 
 
 
 
Email : necchi.andrea@hsr.it 
 
 
 
 
Protocol writing committee:   
Andrea Necchi, Milano 
 
 
 
 
 
Wim P.J. Witjes, Arnhem 
 
 
 
 
 
 
 
 
 
 
 

EAU RF protocol  2018-02 
                                                                                                                                                          
Adjuvant Pemigatinib in surgically treated high-risk UC  
 
 
 
 
 
 
 
 
Final version 2.1, October 4th, 2021 
 
 
CONFIDENTIAL INFORMATION 
      Page 2 of 43 
 
 
Table of Contents 
 
Table of Contents ................................................................................................................................. 2 
List of Abbreviations and Relevant Definitions .................................................................................. 3 
Confidentiality Statement .................................................................................................................... 5 
1. STUDY SYNOPSIS ........................................................................................................................ 6 
2. INTRODUCTION AND RATIONALE .......................................................................................... 9 
3. STUDY OBJECTIVES & ENDPOINTS ...................................................................................... 11 
3.1 Rationale for 2-year relapse-free Survival Endpoint ................................................................... 11 
3.2 Biomarker Research ..................................................................................................................... 11 
4. STUDY DESIGN and PROCEDURES ......................................................................................... 12 
4.1 Study Periods ............................................................................................................................... 12 
4.1.1 Molecular Pre-screening: .................................................................................................. 12 
4.1.2 Screening and Treatment Period: ...................................................................................... 13 
4.1.3 End of Treatment .............................................................................................................. 13 
4.1.4 Safety Follow-up: .............................................................................................................. 13 
4.1.5 Disease Status Follow-up: ................................................................................................. 13 
4.1.6 Survival Follow-up: .......................................................................................................... 14 
4.1.7 End of Study: .................................................................................................................... 14 
4.2 Pre-Treatment Tests ..................................................................................................................... 14 
4.2.1 Informed Consent Forms and Prescreening Molecular Tests ........................................... 14 
4.2.2 Inclusion and Exclusion Criteria ....................................................................................... 15 
4.2.3 Demographic Data and Medical History .......................................................................... 15 
4.2.4 Prior Medications Review ................................................................................................. 15 
4.2.5 Disease Details and Treatments ........................................................................................ 15 
4.2.6 Unique Screening Number ................................................................................................ 15 
4.2.7 Other Pre-treatment Examinations .................................................................................... 15 
4.2.8 Registration Procedure ...................................................................................................... 16 
4.3 Study Treatment ........................................................................................................................... 16 
4.3.1 Supply, Packaging, and Labeling ...................................................................................... 16 
4.3.2 Storage .............................................................................................................................. 16 
4.3.3 Instruction to Subjects for Handling Study Drug (Pemigatinib)....................................... 16 
4.3.4 Treatment Compliance ...................................................................................................... 17 
4.3.5 Adverse Events ................................................................................................................. 17 
4.3.6 Treatment Interruptions and Adjustments......................................................................... 17 
4.3.7 Management of Hyperphosphatemia ................................................................................ 19 
4.3.8 Criteria for permanent discontinuation of study drug ....................................................... 19 
4.4 During Treatment- & Follow-Up Procedures .............................................................................. 20 
4.4.1 Concomitant Medication ................................................................................................... 20 
4.4.2 Other During Treatment Examinations ............................................................................. 20 
4.4.3 Relapse or Progression ...................................................................................................... 20 
4.4.4 Subsequent Anti-Cancer Therapy Status .......................................................................... 21 
4.4.5 Adverse Events ................................................................................................................. 21 
4.5 Pregnancy ..................................................................................................................................... 21 
4.6 Premature Termination of the Study ............................................................................................ 21 
5. PATIENT SELECTION & WITHDRAWAL CRITERIA ............................................................ 22 
5.1 Study Population .......................................................................................................................... 22 
5.2 Inclusion Criteria.......................................................................................................................... 22 
5.3 Exclusion Criteria ........................................................................................................................ 23 
5.4 Patient Withdrawal and Early Dropouts (off study) .................................................................... 24 
6. REPORTING ADVERSE EVENTS ............................................................................................. 25 
6.1 Adverse Events (AE’s) ................................................................................................................. 25 

EAU RF protocol  2018-02 
                                                                                                                                                          
Adjuvant Pemigatinib in surgically treated high-risk UC  
 
 
 
 
 
 
 
 
Final version 2.1, October 4th, 2021 
 
 
CONFIDENTIAL INFORMATION 
      Page 3 of 43 
 
 
6.2 Serious Adverse Events (SAE’s) ................................................................................................. 25 
6.3 Suspected Unexpected Serious Adverse Reactions (SUSAR’s) .................................................. 26 
7. STATISTICAL CONSIDERATIONS ........................................................................................... 27 
7.1 Patient Accrual, Study Duration and Calculation of Patient Numbers ........................................ 27 
7.2 Efficacy Analysis Population ....................................................................................................... 27 
7.3 Safety Analysis Population .......................................................................................................... 27 
7.4 Statistical Analysis ....................................................................................................................... 27 
7.4.1 Demographics, Safety and Tolerability and Biomarkers Analysis ................................... 27 
7.4.2 Relapse Free Survival Analysis and 2 year RFS rate........................................................ 28 
7.4.3 Overall Survival Analysis ................................................................................................. 28 
8. ETHICAL AND ADMINISTRATIVE CONSIDERATIONS; PUBLICATION ......................... 28 
8.1 Ethical and Regulatory Considerations ........................................................................................ 28 
8.2 Study Organisation & Management ............................................................................................. 29 
8.3 Handling and Storage of Data and Documents ............................................................................ 29 
8.4 Amendments ................................................................................................................................ 30 
8.5 General Progress Report .............................................................................................................. 30 
8.6 End of Study Report ..................................................................................................................... 31 
8.7 Steering Committee...................................................................................................................... 31 
8.8 Public Disclosure and Publication Policy .................................................................................... 31 
8.9 Financing and insurance............................................................................................................... 32 
8.10 Risk analysis .............................................................................................................................. 32 
9 REFERENCES................................................................................................................................ 32 
Appendix 1 Contraceptive Guidance and Pregnancy Testing ........................................................... 35 
Appendix 2 Common Terminology Criteria for Adverse Events v 4.0 (CTCAE) ............................ 38 
Appendix 3 Investigator Protocol Signature Sheet ............................................................................ 39 
Appendix 4 WHO Performance Score & NYHA Classification of Heart Failure ............................. 40 
Appendix 5 CYP3A Inhibitors and Inducers ..................................................................................... 41 
Appendix 6 Flowchart and Laboratory Evaluations. ......................................................................... 42 
 
 
List of Abbreviations and Relevant Definitions  
 
AC 
Adjuvant Chemotherapy 
AE 
Adverse Event: any untoward medical occurrence in a patient or clinical trial 
subject administered a medicinal product and which does not necessarily have 
a causal relationship with this treatment. 
ALT 
Alanin-aminotransferase 
AR 
Adverse Reaction: all untoward and unintended responses to an investigational 
medicinal product related to any dose administered. 
AST 
Aspartate-aminotranferase 
CI 
Confidence Interval 
CIS 
Carcinoma In Situ 
CT 
Computer Tomography 
CTCAE 
Common Terminology Criteria for Adverse Events 
DSUR 
Drug Safety Update Report 
EAU (RF) 
European Association of Urology (Research Foundation) 

EAU RF protocol  2018-02 
                                                                                                                                                          
Adjuvant Pemigatinib in surgically treated high-risk UC  
 
 
 
 
 
 
 
 
Final version 2.1, October 4th, 2021 
 
 
CONFIDENTIAL INFORMATION 
      Page 4 of 43 
 
 
ECG 
ElectroCardioGram 
ECOG 
Eastern Cooperative Oncology Group 
eCRF 
Electronic Case Report Form 
EDC 
Electronic Data Capture 
EOT 
End Of Treatment  
EudraCT 
European drug regulatory affairs Clinical Trials  
FGF(R) 
Fibroblast Grow Factor (Receptor) 
FSH 
Follicle Stimulating Hormone 
GC 
Combination of gemcitabine and cisplatin 
GCP 
ICH Harmonised Tripartite Guideline E6: Note for Guidance on Good Clinical 
Practice (CPMP/ICH/135/95) Step 5, adopted by CPMP July 1996. European 
Directives 2001/20/EC and 2005/28/EC and the most recent “REGULATION 
(EU) No 536/2014 OF THE EUROPEAN PARLIAMENT AND OF THE 
COUNCIL of 16 April 2014 on clinical trials on medicinal products for 
human use, and repealing Directive 2001/20/EC”. 
GDPR 
General Data Protection Regulation 
gLOH 
Genome-wide Loss Of Heterozygosity 
HIV 
Human Immunodeficiency Virus 
HRT 
Hormonal Replacement Therapy 
IB 
Investigators Drug Brochure 
ICF 
Informed Consent Form 
IRB/IEC 
Institutional Review Board / Institutional Ethics Committee 
ICPIs 
Immune Checkpoint Inhibitors 
ITT 
Intention To Treat 
LDH 
Lactate Dehydrogenase 
MIBC 
Muscle Invasive Bladder Cancer 
MRI 
Magnetic Resonance Imaging 
MVAC 
Combination of methotrexate, vinblastine, adriamycin, and cisplatin 
NAC 
Neo-adjuvant Chemotherapy 
NYHA 
New York Heart Association 
OS 
Overall Survival 
PD-1 
Programmed Death Ligand 1 
PI 
Principal Investigator 
QD 
Once Daily 
RC 
Radical Cystectomy 
RFS 
Relapse Free Survival 

EAU RF protocol  2018-02 
                                                                                                                                                          
Adjuvant Pemigatinib in surgically treated high-risk UC  
 
 
 
 
 
 
 
 
Final version 2.1, October 4th, 2021 
 
 
CONFIDENTIAL INFORMATION 
      Page 5 of 43 
 
 
RNU 
Radical Nephro Ureterectomy 
SAE 
Serious Adverse Event: A serious adverse event is any untoward medical 
occurrence that at any dose: results in death; is life-threatening; requires 
inpatient hospitalisation or prolongation of existing hospitalization; results in 
persistent or significant disability or incapacity or is a congenital 
anomaly/birth defect. 
SUSAR 
Suspected Unexpected Serious Adverse Reaction: A serious adverse reaction, the 
nature, or severity of which is not consistent with the applicable product 
information (e.g. summary of product characteristics for an authorised 
product. 
Sponsor 
The sponsor is the party that commissions the organisation or performance of the 
research, for example a pharmaceutical company, academic hospital, scientific 
organisation or investigator. A party that provides funding for a study but does 
not commission it is not regarded as the sponsor, but referred to as a 
subsidising party. 
TMB 
Tumor Mutational Burden 
UC 
Urothelial Carcinoma 
ULN 
Upper Limit of Normal 
US 
United States of America 
WBC 
White Blood Cells 
WHO  
World Health Organisation 
WOCBP 
Women Of Child Bearing Potential 
 
Confidentiality Statement 
 
These materials contain confidential information belonging to the EAU Research Foundation (EAU 
RF) except as may be otherwise agreed to in writing, by accepting or reviewing these materials, you 
agree to hold such information in confidence and not to disclose it to others (except where required 
by applicable law) nor use it for unauthorized purposes. In the event of actual or suspected breach 
of this obligation, the EAU RF should be promptly notified. 
 
 
 
 
 
 
 
 
 
 
 

EAU RF protocol  2018-02 
                                                                                                                                                          
Adjuvant Pemigatinib in surgically treated high-risk UC  
 
 
 
 
 
 
 
 
Final version 2.1, October 4th, 2021 
 
 
CONFIDENTIAL INFORMATION 
      Page 6 of 43 
 
 
1. STUDY SYNOPSIS 
 
Study 
Title 
and number 
Open-label, single-arm, Phase II study, evaluating safety and efficacy of 
INCB054828 (Pemigatinib) as adjuvant therapy for molecularly-selected, high-
risk patients with urothelial carcinoma who have received radical surgery.  
A European Association of Urology Research Foundation Phase II Clinical 
Trial. EAU RF number: 2018-02. 
Rationale 
 Patients with invasive disease at radical resection of Urothelial Carcinoma 
(UC) are at high risk of relapse and may benefit from additional cisplatin-
based chemotherapy. 
 Patients whose disease progresses on platinum-based chemotherapy or who 
are ineligible due to inadequate renal function or poor performance status 
have limited treatment options. In such patients treatments using new agents 
should be considered. 
 Patients who received neo-adjuvant platinum-based chemotherapy who 
have residual disease at radical resection of UC have a worse prognosis and 
should be considered with additional treatments using new agents. 
 Immune checkpoint inhibitors (ICPIs) have improved outcomes in some 
patients with platinum-resistant and/or -ineligible metastatic UC; however, 
benefit may be limited to patients with higher positive tumor and infiltrating 
immune cell staining for programmed death-ligand-1 (PD-1). 
 Fibroblast growth factor (FGF) / FGF receptor (FGFR) genetic alterations 
are implicated in the pathogenesis of UC, most commonly FGFR3 
mutations(≈ 12%) and translocations (≈ 3-6%). FGFR3 genetic alterations 
are more common in patients with immune desert luminal cluster I subtype 
UC; these patients are expected to receive less benefit from ICPIs. 
 Pemigatinib is a selective, potent, oral inhibitor of FGFR1, 2, and 3, and has 
shown efficacy in tumors with various FGFR alterations. 
 
Objectives 
 The primary objective of this study is to evaluate 2-year relapse free survival 
rate of high-risk patients previously treated with cisplatin-based 
chemotherapy or ineligibility to receive cisplatin-based adjuvant 
chemotherapy. These patients will receive adjuvant Pemigatinib after radical 
surgery of their urothelial carcinoma. 
 Secondary objectives are to evaluate safety, tolerability and overall survival. 
 An explorative objective is to evaluate biomarkers of clinical benefit and 
prognostic biomarkers. These biomarkers will be evaluated at the time of 
radical surgery, on the residual post-chemotherapy tumor tissue, before the 
administration of the study drug. 
 
Study Design 
& 
Intervention 
This is an open-label, single-arm, phase 2 study. Patients will receive 
Pemigatinib at a once-daily (QD) dose of 13.5 mg on a continuous schedule. 
Treatment will be continued until 12 months, or until the evidence of disease 
relapse or onset of unacceptable toxicity. 
Hyperphosphatemia can be managed with diet modification, phosphate binders, 
or dose modification. Since mineralization of the cornea and retinal changes 
consisting of serous retinal detachment have been reported in humans, 
ophthalmic exams are done at baseline and once every 12 weeks during 
treatment and should include a visual acuity test, slit-lamp examination and 
fundoscopy. Additional assessments (eg. Orbital CT) should be done if 
clinically relevant retinal findings are observed on ophthalmologic exams and 

EAU RF protocol  2018-02 
                                                                                                                                                          
Adjuvant Pemigatinib in surgically treated high-risk UC  
 
 
 
 
 
 
 
 
Final version 2.1, October 4th, 2021 
 
 
CONFIDENTIAL INFORMATION 
      Page 7 of 43 
 
 
in participants with reported visual AEs or change in visual acuity, if the events 
or changes are suspected to be of retinal origin. 
Study 
Population 
A total of 56 patients with pT3-4 and/or pN1-3 stage UC at radical cystectomy 
or radical nephroureterectomy with documented FGF/FGFR alterations.  
 
Key Inclusion Criteria: 
 Men and woman, aged 18 years or older with histological evidence of pT3-
4 and/or pN1-3 UC of the urinary bladder or upper urinary tract after 
radical cystectomy / radical nephroureterectomy. Patients with mixed 
histologies are required to have a dominant (i.e. at least 50%) urothelial 
cell carcinoma pattern. 
 Previous administration of at least 2-3 cycles of neoadjuvant cisplatin-based 
chemotherapy OR, if neoadjuvant chemotherapy was not administered, 
ineligibility to receive cisplatin-based adjuvant chemotherapy based on 
Galsky’s criteria, that include at least one of the following: (1) WHO 
performance status ≥ 2 and/or (2) creatinine-clearance < 60 ml/min and/or 
(3) CTCAE Gr ≥ 2 hearing loss and/or (4) CTCAE Gr ≥ 2 neuropathy. 
 Evidence of FGFR3 alterations (mutations or gene fusions as specified in 
protocol) as assessed by a centralized Foundation Medicine test (Foundation 
One CDx assay). 
 Recovered with no evidence of disease confirmed by radiological images, 
prior to start of adjuvant therapy within 13 weeks after radical surgery. 
 Willingness to avoid pregnancy or fathering children. 
 Written informed consent for screening of tumor tissue and if evidence of 
FGFR alterations written informed consent for the start of the complete 
study. 
 
Key Exclusion Criteria: 
 Any previous receipt of a selective FGFR inhibitor. 
 Presence of primary CIS only. 
 Presence of another malignancy in the 3 years before enrolment except for 
basal cell carcinoma or squamous cell carcinoma of the skin, cis of cervix, 
localised prostate cancer in active surveillance or other non invasive or other 
indolent malignancy that has undergone potentially curative therapy. 
 Presence of pregnancy or lactation or not willing to avoid pregnancy or 
fathering children. 
 Distant metastases (M1 disease) or presence of radiological evidence of 
disease at baseline. 
 Treatment with other investigational drugs, receipt of anticancer 
medications (except for neoadjuvant cisplatin-based chemotherapy, see 
second inclusion criterion) or radiotherapy of the bladder or upper urinary 
tract prior to - or after radical surgery. 
 Use of any potent CYP3A4 inhibitors or inducers within 14 days or 5 half 
lives (whichever is longer) before the first dose of study treatment. 
 Abnormal laboratory parameters: 
o Total bilirubin ≥ 1.5 × upper limit of normal (ULN; ≥ 2.5 × ULN if 
Gilbert syndrome). 
o AST and/or ALT > 2.5 × ULN  
o Creatinine clearance ≤ 30 mL/min based on Cockroft-Gault. 
o Serum phosphate > institutional ULN. 

EAU RF protocol  2018-02 
                                                                                                                                                          
Adjuvant Pemigatinib in surgically treated high-risk UC  
 
 
 
 
 
 
 
 
Final version 2.1, October 4th, 2021 
 
 
CONFIDENTIAL INFORMATION 
      Page 8 of 43 
 
 
o Serum calcium outside of the institutional normal range or serum 
albumin-corrected calcium outside of the institutional normal range 
when serum albumin is outside of the institutional normal range.  
 History of human immunodeficiency virus infection or active tuberculosis 
infection. 
 Diagnosis of immunodeficiency or receiving chronic systemic steroid 
therapy (exceeding > 10 mg daily of prednison equivalent; inhalation 
steroids are permitted). 
 Evidence of hepatitis B virus or hepatitis C virus active infection or risk of 
reactivation. 
 Severe hepatic impairment. 
 Known prior severe hypersensitivity to investigational product or its 
excipients. 
 History of clinically significant or uncontrolled cardiac disease, including 
unstable angina, acute myocardial infarction within 6 months of enrolment, 
New York Heart Association Class III or IV (Appendix 4). 
 Current evidence of corneal disorder/keratopathy (including but not limited 
to bullous/band keratopathy, corneal abrasion, inflammation/ulceration, 
keratoconjunctivitis, etc) or retinal disorder (including but not limited to, 
central serous retinopathy, macular/retinal degeneration, diabetic retino-
pathy, retinal detachment, etc) as confirmed by ophthalmologic 
examination. 
 Any condition that would, in the investigator's judgment, interfere with full 
participation in the study, including administration of study drug and 
attending the required study visits. 
 
Main 
study 
Endpoints 
 Primary endpoint: 2-year relapse free survival rate. 
 Secondary endpoints:  Overall survival and incidence and severity of side 
effects, biomarkers evaluation. 
 Safety aspects: changes in laboratory values. 
Nature 
and 
extent of the 
burden and 
risks 
associated 
with 
participation 
and 
risk- 
benefit 
This is a phase II study with a drug that has indicated promising effects for 
relapse free survival in this high-risk group of patients. On the other hand, there 
are side effects that should be managed with dose reduction or stop; frequent 
laboratory checks or other supportive measures in consultation with a medical 
oncologist. Further, at relapse or progression, subjects will be asked to sign a 
consent to allow a biopsy of the relapse or metastases and tumor tissue to be sent 
to the sponsor's central laboratory (Foundation Medicine) for genetic 
sequencing. Based on the current available information of Pemigatinib, the risks 
related to the expected treatment outcome, quality and quantity of side effects 
of the study medication can be considered as acceptable. 
Timing 
The study includes a 2-year recruitment phase, followed by a 1-year treatment 
and subsequent follow-up phase. 
 Protocol ready: June 2019 
 Start EC submission procedure: September 2019 
 Start Initiation of the centers: April 2020 
 Last patient follow up: April 2024 
 Study Closure: 2024. 
 
 
 
 

EAU RF protocol  2018-02 
                                                                                                                                                          
Adjuvant Pemigatinib in surgically treated high-risk UC  
 
 
 
 
 
 
 
 
Final version 2.1, October 4th, 2021 
 
 
CONFIDENTIAL INFORMATION 
      Page 9 of 43 
 
 
 
2. INTRODUCTION AND RATIONALE 
 
About 1.7 million new cases of cancer have been diagnosed in 2018 in the US with urothelial 
carcinoma located in the urinary bladder being the 4th most common cancer in males [1]. Amongst 
them, 20% are non-metastatic muscle invasive bladder cancers (stage pT2-4N0M0) for which 
radical cystectomy can provide optimal local control. Most urothelial tumors originate in the urinary 
bladder (90%) or upper urinary tract (~10% in renal pelvis/ureter). Invasive tumors in the upper 
urinary tract are typically managed with radical resection alone (radical nephroureterectomy (RNU) 
or radical ureterectomy (RU)). Standard of care treatment for muscle invasive bladder cancer 
(MIBC) is cisplatin based neo-adjuvant chemotherapy followed by radical cystectomy (RC)[2]. 
However, surgery often remains insufficient for cure and up to 30% of the patients will eventually 
develop recurrence, either local pelvic or distant metastases within 2 years [3]. Therefore, effective 
systemic treatment must be initiated to treat metastases that are not visible at the time of surgery. 
Cisplatin-based regimens are effective and, in a neoadjuvant setting, they improve the absolute 
overall survival by 5% and the specific survival by 9% [4]. Various combinations have been 
assessed and the most efficient so far are either the combination of methotrexate, vinblastine, 
adriamycin, and cisplatin (MVAC), or the less toxic combination of gemcitabine and cisplatin (GC). 
Both are considered equally effective. In a meta-analysis of 17 studies, the average complete 
response rate on bladder specimen (pT0) following neoadjuvant cisplatin (NAC) was between 10 
and 46% [5-8]  Complete response rate after NAC can be used as a surrogate marker of specific 
survival with a 5 year specific survival rate of 80% [9]. However despite NAC, 19% of patients are 
found to have lymph node- positive disease on postoperative pathological analysis [9,10]. The 
presence of lymph node metastatic disease is a well known independent prognostic factor of overall 
survival in patients with MIBC [3,9]. Multi-institutional case series report a 70% 5-year survival 
rate in patients with no lymph node disease compared with < 40% in those positive for lymph node 
metastases [3]. In a study including 150 patients who had node-positive disease despite RC and 
NAC, Kassouf et al reported a significant recurrence-free survival advantage (HR, 0.29; 95% CI, 
0.10-0.81, p=0.02) with a trend towards significance in prolonged overall survival (HR, 044; 95% 
CI, 0.18-1.11, p=0.08) in 37 patients treated with Adjuvant Chemotherapy (AC) [11]. A possible 
implication of such data is that patients with positive nodes on histopathology might benefit from 
adjuvant, second-line chemotherapy. A recent meta-analysis by Leow et al. and a study by Millikan 
do concur with this [12, 13]. However, there is little evidence on how bladder cancer patients with 
positive lymph nodes after radical cystectomy and NAC should be managed and currently, no 
treatment is approved as second-line chemotherapy for a progressive disease despite RC and NAC. 
Patients with invasive disease at radical resection of Urothelial Carcinoma (UC) are at high risk of 
recurrence and may benefit from additional cisplatin-based chemotherapy [3,13]. In current daily 
practice, patients who have invasive residual disease at radical resection and have not received neo-
adjuvant cisplatin may go on to receive adjuvant cisplatin based chemotherapy [2] which, despite 
not having shown definitive clinical benefit, is used in 22% of patients undergoing radical 
cystectomy in the US [12.] . Up to 60% of patients who undergo radical cystectomy are not 
candidates for adjuvant cisplatin based chemotherapy because they received neoadjuvant 
chemotherapy or they are cisplatin ineligible or they experienced post-operative problems such as 
decreased performance status or deterioration of renal function [14] This population has a 
significant unmet need as there are no treatment options available to help reduce the risk of 

EAU RF protocol  2018-02 
                                                                                                                                                          
Adjuvant Pemigatinib in surgically treated high-risk UC  
 
 
 
 
 
 
 
 
Final version 2.1, October 4th, 2021 
 
 
CONFIDENTIAL INFORMATION 
      Page 10 of 43 
 
 
recurrence and improve survival. The checkpoint inhibition approach is attractive in this setting 
considering the lack of effective, available treatment options and the positive preliminary results 
with PD-1/PD-L1 blockade in advanced bladder cancer. [15]. However benefit may be limited to 
patients with higher positive tumor and infiltrating immune cell staining for programmed death-1 
ligand-1 (PD-1). Multiple clinical trials are currently exploring the efficacy of immune checkpoint 
inhibitors in this setting [16] 
 
Alterations in fibroblast growth factor receptor (FGFR) gene (eg, mutations or fusions) are 
common; in stage ≥ T2 bladder cancer, 5%-20% of patients have point mutations in 
FGFR3, and 40% have upregulated expression of FGFR3 protein. Alterations in FGFR type 3 
(FGFR3) are particularly frequent in patients with immunologically “cold” luminal I subtype UC 
[17,18]. Aberrant signaling through FGFR resulting from gene amplification or mutation, 
chromosomal translocation, and ligand-dependent activation of the receptors has been demonstrated 
in multiple types of human cancers, including urothelial cancers. FGFR signaling contributes to the 
development of malignancies by promoting tumor cell proliferation, survival, migration, and 
angiogenesis [19].  
 
Pemigatinib is an inhibitor of the FGFR family of receptor tyrosine kinases that is proposed for the 
treatment of advanced malignancies [20].  
 
Fibroblast Growth Factor Receptor Inhibitor in Oncology and Hematology Trial (fight)-201 is a 
phase 2, open-label, multicenter study to evaluate the efficacy and safety of Pemigatinib in patients 
with metastatic or surgically unresectable UC harboring FGFR3 mutations and translocations 
(cohort A) and other FGF/FGFR genetic alterations (cohort B) (NCT02872714). Interim results of 
the (fight)-201 trial have been recently presented (Necchi A; et al. ESMO 2018 annual meeting).  
Patients with FGFR3 mutations/fusions (cohort A) or other FGF/FGFR genetic alterations (cohort 
B) were enrolled and received Pemigatinib 13.5 mg orally once daily (QD) on a 21-day cycle (2 
weeks on/1 week off) until disease progression or unacceptable toxicity. At data cutoff (July 6, 
2018), 108 patients were enrolled. The efficacy-evaluable population consisted of 103 patients, and 
the safety-evaluable population consisted of 108 patients (5 patients did not have FGF/FGFR 
alterations confirmed through the sponsor’s central laboratory). Among 103 patients, 61 were 
enrolled in cohort A and 42 in cohort B. Of 61 patients in cohort A, 49 discontinued treatment and 
12 had treatment ongoing.  
The objective response rate (ORR) in cohort A was 21% (95% CI, 12%-34%) and included 13 
confirmed partial responses (PRs). A total of 22 patients had stable disease (SD), including 1 
unconfirmed PR in an ongoing patient who had not yet had a confirmatory scan. In cohort B, 1 
patient had a confirmed PR; 1 patient with FGF10 amplification had an unconfirmed PR. Median 
duration of response (DOR) in cohort A was 6 months, and median PFS was 4 months (95% CI, 
3.0-5.6 months). The 3-month PFS in cohort A was 63% (95% CI, 49.4%-73.9%).  
Most common treatment-related adverse events (TRAE) included hyperphosphatemia, diarrhea, 
alopecia, constipation, and stomatitis. As a more intense treatment regimen may increase the 
efficacy of Pemigatinib, the protocol has been amended to enroll patients with FGFR3 
mutations/fusions on a continuous dosing schedule, with the starting dose of 13.5 mg. 
 
EAU RF is proposing to study Pemigatinib for the treatment of high risk patients after radical 

EAU RF protocol  2018-02 
                                                                                                                                                          
Adjuvant Pemigatinib in surgically treated high-risk UC  
 
 
 
 
 
 
 
 
Final version 2.1, October 4th, 2021 
 
 
CONFIDENTIAL INFORMATION 
      Page 11 of 43 
 
 
surgery with fibroblast growth factor (FGF)/FGFR genetic alterations [21].  
 
 
3. STUDY OBJECTIVES & ENDPOINTS 
 
The primary objective of this study is to evaluate the 2-year relapse-free survival rate (RFS) of 
high-risk patients previously treated with cisplatin-based chemotherapy or ineligibility to receive 
adjuvant cisplatin-based chemotherapy. These patients will receive adjuvant Pemigatinib after 
radical surgery of their urothelial carcinoma. 
Secondary objectives are to evaluate safety, tolerability and overall survival.  
An explorative objective is to evaluate biomarkers of clinical benefit and prognostic biomarkers. 
These biomarkers will be evaluated at the time of radical surgery, on the tumor tissue, before the 
administration of the study drug. 
 
3.1 Rationale for 2-year relapse-free Survival Endpoint 
 
Improvement of RFS may be regarded as an optimal endpoint for adjuvant therapy trials, given the 
availability of multiple lines of new therapies in the advanced stages that may affect RFS outcomes 
in these patients. 
 
3.2 Biomarker Research 
 
The aim of biomarker research is to evaluate biomarkers of clinical benefit and prognostic 
biomarkers in patients receiving adjuvant treatment with pan-FGFR inhibitor Pemigatinib. These 
biomarkers will be evaluated at the time of radical surgery, on the tumor tissue, before the 
administration of the study drug. The biomarkes will be evaluated on paraffin-embedded tumor 
tissue from radical surgery, and will rely on next-generation sequencing technology. Tumor samples 
will be centralized to Foundation Medicine for molecular evaluation, Address: Central Laboratory 
Foundation Medicine GmbH, Nonnenwald 2, 82377 Penzberg, Germany. 
In case of neo-adjuvant chemotherapy, the proposed setting will be ideal to access tumor tissue that 
can be representative of a chemo-resistant disease assessed immediately before starting the study 
drug. 
Tumor specimens will be used to analyze biomarkers. Comprehensive genomic profiling (CGP) 
will be performed with a hybrid capture-based next-generation sequencing assay (FoundationONE-
CDx). 
CGP will be performed on hybridization-captured, adaptor ligation-based libraries to a median 
coverage depth of 743× for 395 cancer-related genes plus select introns from 31 genes frequently 
rearranged in cancer. Results will be analyzed for base substitutions, short insertions/deletions 
(indels), rearrangements, and copy number alterations (amplification and homozygous deletion). 
Custom filtering will be applied to remove benign germline events as described. Reportable 
Genomic Alterations will be called as known if the specific variant is present in the Catologue Of 
Somatic Mutations In Cancer database, if the variant has been characterized as pathogenic, or if the 
variant has likely functional status (disruptive alterations in tumor suppressor genes); all other 
variants will be classified as variants of unknown significance. 

EAU RF protocol  2018-02 
                                                                                                                                                          
Adjuvant Pemigatinib in surgically treated high-risk UC  
 
 
 
 
 
 
 
 
Final version 2.1, October 4th, 2021 
 
 
CONFIDENTIAL INFORMATION 
      Page 12 of 43 
 
 
To determine microsatellite status, 114 intronic homopolymer repeat loci on the FoundationOne-
CDx panel will be analyzed for length variability and compiled into an overall Micro Satellelite 
Instability score via principal components analysis. Tumor mutational burden (TMB) will be 
calculated as the number of somatic base substitutions or indels per megabase (Mb) of the coding 
region target territory of the test (1.1 Mb) after filtering to remove known somatic and deleterious 
mutations and extrapolating that value to the exome or genome as a whole. TMB will be 
categorized as low (<6 mutation [mut]/Mb), intermediate (6–20 mut/Mb), or high (≥20 mut/Mb). 
Germline and somatic status for mutations will be determined without matched normal tissue as 
described. Percent genome-wide loss of heterozygosity (gLOH) will be used as a marker of 
homologous recombination deficiency and calculated as described and a gLOH score of ≥14% was 
defined as gLOH-High.  
 
 
 
 
4. STUDY DESIGN and PROCEDURES 
 
This is an open-label, single-arm, phase 2 study. Patients will receive Pemigatinib at a once-daily 
(QD) starting dose of 13.5 mg on a continuous dose regimen. Treatment will be continued until 12 
months, or until the evidence of disease relapse or onset of unacceptable toxicity. The study 
includes a 2-year recruitment phase, followed by a 1-year treatment and subsequent follow-up 
phase.  
 
A radiological assessment of disease status will be performed at screening (after radical surgery). 
Subsequently, disease status will be assessed according to daily urological practice until the start of 
new anticancer therapy, disease relapse, death or end of study. Follow-up imaging scans are usually 
based on the recurrence possibility (timing, probability, site, and potential treatment) and functional 
aspects. In spite of low level of evidence, a suggested oncologic follow-up schedule includes CT 
scans every 4 months during the first year and every 6 months until the third year [22]. During the 
investigators meeting at the occasion of the annual EAU meeting in Barcelona, on March 17th, 
2019, the investigators proposed and agreed to use a 12 weeks interval (+/- 1 week) for imaging 
procedures in this high risk group of patients. Relapse free survival will be assessed starting from 
date of first dose and then every 12 weeks until disease relapse or death. Final assessment of the 2-
year relapse free survival rate will be done at 2 years. Overall survival will be assessed from the 
first dose until death (every 12 weeks from disease relapse to death or termination of the study). 
(See Appendix 6) 
 
4.1 Study Periods 
 
4.1.1 Molecular Pre-screening: 
Prescreening will be performed on tumor samples from the RC/RNU specimens. Potential subjects 
will give their consent for testing of their tumor tissue, whereafter they can be screened/enrolled 
based on local genomic sequencing outcome at the sponsor's central laboratory. The timing of pre-
screening consent can be prior to,- or after RC/RNU. 
 

EAU RF protocol  2018-02 
                                                                                                                                                          
Adjuvant Pemigatinib in surgically treated high-risk UC  
 
 
 
 
 
 
 
 
Final version 2.1, October 4th, 2021 
 
 
CONFIDENTIAL INFORMATION 
      Page 13 of 43 
 
 
4.1.2 Screening and Treatment Period: 
After signing the informed consent form for the complete study, the screening period will then take 
place in the period after surgery until week 13 after surgery. At Day 1, prior to the start of 
treatment, results from screening visit evaluations should be reviewed to determine whether the 
subject continues to meet the eligibility requirements. Subsequent visits during the treatment phase 
will take place at Day 8, Day 15 and Day 21 and subsequently at 3 week intervals. Timing of 
subsequent visits can be prolonged to max. 9 week intervals if no problems exist during the first 12 
weeks of therapy. Dates for subsequent study visits will be determined based on Day 1, the start of 
treatment, and should occur within 3 days (±) of the scheduled date unless delayed for safety 
reasons. 
 
Subjects will self-administer study drug using an oral QD regimen in a continuous dosing schedule. 
Each dose of Pemigatinib should be taken first thing in the morning upon waking or after a 2-hour 
fast; subjects should then fast for an additional 1 hour after taking study drug. The starting dose is 
13.5 mg Pemigatinib. Study treatment will continue until 12 months, or until the evidence of disease 
relapse or onset of unacceptable toxicity. 
  
If a dose is missed by more than 4 hours, the subject should skip the dose and take the next 
scheduled dose at the usual time. Any missed doses reported by the subject should be recorded in 
the subject's source documents.  
 
4.1.3 End of Treatment  
When the subject permanently discontinues study drug, the end of treatment (EOT) visit should be 
conducted. If the EOT visit coincides with a regular study visit, the EOT evaluations will supersede 
those of that scheduled visit, and the data should be entered in the EOT visit in the eCRF. The 
subject should be encouraged to return for the follow-up visit. 
 
4.1.4 Safety Follow-up: 
The safety follow-up period is the interval between the EOT visit and the scheduled follow-up visit, 
which should occur 30 to 35 days after the EOT visit (or after the last dose of study drug if the EOT 
visit was not performed). Adverse events and SAEs must be reported until at least 30 days after the 
last dose of study drug; or until toxicities resolve, return to baseline, or are deemed irreversible; 
death; or initiation of a new anticancer treatment, whichever occurs first. Reasonable efforts should 
be made to have the subject return for the follow-up visit and report any AEs that may occur during 
this period. 
If a subject is scheduled to begin a new anticancer therapy before the end of the 30-day safety 
follow-up period, the safety follow-up visit should be performed before new anticancer therapy is 
started. Once new anticancer therapy has been initiated, the subject will move into the survival 
follow-up period. 
 
4.1.5 Disease Status Follow-up: 
Subjects who discontinue study treatment for a reason other than disease relapse or progression will 
move into the disease status follow-up period and should be assessed every 12 weeks by radiologic 

EAU RF protocol  2018-02 
                                                                                                                                                          
Adjuvant Pemigatinib in surgically treated high-risk UC  
 
 
 
 
 
 
 
 
Final version 2.1, October 4th, 2021 
 
 
CONFIDENTIAL INFORMATION 
      Page 14 of 43 
 
 
imaging to monitor disease status. Every effort should be made to collect information regarding 
disease status until: 
• The start of new antineoplastic therapy. 
• Disease relapse or progression. 
• Death. 
• The end of the study. 
At disease relapse or progression, a biopsy and subsequent genomic sequencing at the sponsors 
central laboratory is recommended after written informed consent of the patient.  
 
4.1.6 Survival Follow-up: 
Once a subject has confirmed disease relapse or progression, or starts a new anticancer therapy, the 
subject moves into the survival follow-up period and should be contacted by telephone, email, or 
visit at least every 12 weeks to assess for survival status until death, withdrawal of consent, or the 
end of the study, whichever occurs first. The investigator or qualified representative can also use 
continuing subject records to report data on subsequent treatment regimens,and overall survival in 
the eCRF.  
 
4.1.7 End of Study: 
The end of the study may be designated as the timepoint when all subjects have discontinued the 
study after 2 years of follow-up or when the sponsor terminates the study. 
 
4.2 Pre-Treatment Tests 
 
4.2.1 Informed Consent Forms and Prescreening Molecular Tests 
Subjects must have confirmation of an FGF/FGFR alteration to be considered for the study. 
Therefore, subjects will be asked to sign a pre-screening consent to allow tumor tissue to be sent to 
the sponsor's central laboratory (Foundation Medicine) for genetic sequencing. The timing of pre-
screening consent can be prior to,- or after RC/RNU. The process of genetic sequencing will take 
approximately 14 days. Once genetic sequencing has confirmed an FGF/FGFR alteration, a valid 
informed consent for enrollment in the complete study must be obtained from the study subject 
before conducting any study-specific procedures.  
The Investigator must obtain documented consent from each potential participant prior to 
participating in a clinical trial. Consent must be documented by the participant’s dated signature or 
by the participant’s legally acceptable representative’s dated signature on a consent form along with 
the dated signature of the person conducting the consent discussion. A copy of the signed and dated 
consent forms should be given to the participant after signature.  
Similarly at relapse or progression, subjects will be asked to sign a consent to allow a biopsy and 
subsequent tumor tissue to be sent to the sponsor's central laboratory (Foundation Medicine) for 
genetic sequencing. 
 
The initial informed consent form, any subsequent revised written informed consent form and any 
written information provided to the participant must receive the IRB/IEC’s approval/favorable 
opinion in advance of use. The participant or his/her legally acceptable representative should be 
informed in a timely manner if new information becomes available that may be relevant to the 
participant’s willingness to continue participation in the trial. The communication of this 

EAU RF protocol  2018-02 
                                                                                                                                                          
Adjuvant Pemigatinib in surgically treated high-risk UC  
 
 
 
 
 
 
 
 
Final version 2.1, October 4th, 2021 
 
 
CONFIDENTIAL INFORMATION 
      Page 15 of 43 
 
 
information will be provided and documented via a revised consent form or addendum to the 
original consent form that captures the participant’s dated signature or by the participant’s legally 
acceptable representative’s dated signature. The informed consent will adhere to IRB/IEC 
requirements, applicable laws and regulations and Sponsor requirements. The informed consent 
process for each subject must be documented in writing within the subject source documentation. 
 
4.2.2 Inclusion and Exclusion Criteria 
All inclusion and exclusion criteria will be reviewed by the investigator or qualified designee to 
ensure that the participant qualifies for the trial.  
 
4.2.3 Demographic Data and Medical History 
Demographic data such as sex and age will be assessed and recorded by the investigator or a 
qualified designee. A medical history will be obtained by the investigator or qualified designee.  
Medical history will include all active conditions, and any condition diagnosed within the prior 10 
years that are considered to be clinically significant by the Investigator.  Details regarding the 
disease for which the participant has been enrolled in this study will be recorded separately and not 
listed as medical history.   
 
4.2.4 Prior Medications Review 
The investigator or qualified designee will review prior medication use, and record prior medication 
taken by the participant within 28 days before starting the trial. Treatment for the disease for which 
the participant has been enrolled in this study will be recorded separately and not listed as a prior 
medication.  
 
4.2.5 Disease Details and Treatments 
The investigator or qualified designee will obtain prior and current details regarding disease status 
and all prior cancer treatments including systemic treatments, radiation and surgeries. 
 
4.2.6 Unique Screening Number 
All consented participants will be given a unique screening number that will be used to identify the 
participant for all procedures. Each participant will be assigned only one screening number.  
 
4.2.7 Other Pre-treatment Examinations 
The investigator or qualified designee will obtain results of molecular pre-screening, physical 
examination (length, weight, pulse, blood pressure), WHO performance status, New York Heart 
Association (NYHA) status, ECG, laboratory and radiological tests as described in the flowchart 
(Appendix 6). A comprehensive eye-examination should be performed by a qualified 
ophthalmologist at screening, once every 12 weeks (± 7 days), at EOT if abnormalities were shown 
at the previous, latest examination, and as clinically indicated.  The eye-examination should include 
a visual acuity test, slit-lamp examination, and funduscopy with digital imaging.  Additional 
assessments (eg, Orbital CT) should be done if clinically relevant retinal findings are observed on 
ophthalmologic exams and in participants with reported visual AEs or change in visual acuity, if the 
events or changes are suspected to be of retinal origin.  Every effort should be made to ensure that 
all subsequent examinations are performed by the same ophthalmologist. 
 

EAU RF protocol  2018-02 
                                                                                                                                                          
Adjuvant Pemigatinib in surgically treated high-risk UC  
 
 
 
 
 
 
 
 
Final version 2.1, October 4th, 2021 
 
 
CONFIDENTIAL INFORMATION 
      Page 16 of 43 
 
 
4.2.8 Registration Procedure 
If the patient satisfies all selection criteria, registration of enrollment of a patient in the complete 
study will be done by the investigator or a qualified representative in the eCRF. For registration the 
following information will be needed: 
 Institutions name 
 Name of investigator 
 Date of informed consent of the complete study 
At registration, a number will be allocated to the patient (patient study inclusion number). This 
number identifies the patient and must be reported on all eCRF’s and other relevant documents. 
This patient sequential identification number identifies the patient for the Sponsor. The local 
investigator and his personnel maintain a list which identifies the patients’ sequential identification 
number with the patients source data. This list is safeguarded by the local investigator and his 
personnel. 
 
4.3 Study Treatment 
 
The investigator shall take responsibility for and shall take all steps to maintain appropriate records 
and ensure appropriate supply, storage, handling, distribution and usage of investigational product 
in accordance with the protocol and any applicable laws and regulations. 
 
4.3.1 Supply, Packaging, and Labeling  
Study drug will be supplied as 2 mg and 4.5 mg tablets. Pemigatinib tablets will be packaged in 
high-density polyethylene bottles. No preparation is required.  
All Incyte investigational product labels will be in the local language and will comply with the legal 
requirements of each country.  
 
4.3.2 Storage  
Pemigatinib drug product should be stored as detailed on the investigational product labeling.  
 
4.3.3 Instruction to Subjects for Handling Study Drug (Pemigatinib)  
The subject must be instructed in the handling of study drug as follows:  
 To store the study drug at room temperature.  
 To only remove from the study drug bottle the number of tablets needed at the time of 
administration.  
 Not to remove doses in advance of the next scheduled administration.  
 To make every effort to take doses on schedule.  
 To report any missed doses.  
 To take study drug immediately upon rising or after a 2-hour fast with a glass of water; the 
subject should refrain from eating 1 hour after taking study drug.  
 If the subject vomits after taking study drug, the subject should not take another dose.  
 To keep study drug in a safe place and out of reach of children.  
 To bring all used and unused study drug bottles to the site at each visit.  

EAU RF protocol  2018-02 
                                                                                                                                                          
Adjuvant Pemigatinib in surgically treated high-risk UC  
 
 
 
 
 
 
 
 
Final version 2.1, October 4th, 2021 
 
 
CONFIDENTIAL INFORMATION 
      Page 17 of 43 
 
 
 If a dose of Pemigatinib is missed by more than 4 hours, that dose should be skipped and the 
next scheduled dose should be administered at the usual time.  
 
4.3.4 Treatment Compliance  
Compliance with all study-related treatments should be emphasized to the subject by the site 
personnel, and appropriate steps should be taken to optimize compliance during the study. 
Compliance with Pemigatinib will be calculated by the sponsor based on the drug accountability 
documented by the site staff and monitored by the sponsor/designee (tablet counts). Subjects will be 
instructed to bring all study drugs with them to the study visits in order for site personnel to conduct 
tablet counts to assess study drug accountability. The drug accountability documentation will be 
used by the sponsor to calculate treatment compliance. 
 
4.3.5 Adverse Events 
The most common treatment-emergent adverse events in more than 20% of the patients receiving  
continuous dose Pemigatinib monotherapy for advanced malignancies were hyperphosphataemia 
(70%), stomatitis (48%), diarrhea (39%), hair loss (38%), dry mouth (37%), dysgeusia (36%), 
fatigue (29%), constipation (33%), decreased appetite (27%), nausea (26%), dry eyes (22%), 
anaemia (21%), asthenia (21%) and palmar-plantar erythrodysaesthesia syndrome (21%) (21). 
Hyperphosphatemia can lead to symptoms such as muscle cramps and contractions, numbness or 
tingling in the mouth. A hyperphosphatemia can be managed with diet modification, phosphate 
binding drugs or dose modification.  
 
Other common adverse events observed in 10-20% of the patients were abdominal pain, vomiting, 
backpain, epistaxis, dry skin, increased blood creatinine level, joint pain, decrease of weight, 
oedema, nail problems, hypercalcaemia, urinary tract infection, pain in extremity and low sodium 
blood levels (21).  
 
Less common adverse events observed in less than 10% of the patients are pyrexia, dehydration and 
hypophosphatemia. 
 
Ophthalmic exams are done at baseline and at least once every 12 weeks during treatment. 
Additional assessments will be done in participants with reported changes in vision. 
 
4.3.6 Treatment Interruptions and Adjustments 
Dose interruptions and modifications may occur for individual study subjects. The occurrence of 
toxicities (related or unrelated to study drug) will guide decisions for treatment interruptions and 
discontinuation for individual subjects. Treatment with Pemigatinib may be interrupted up to 14 
days to allow for resolution of toxicity. Subjects may resume treatment if no medical condition or 
other circumstance exists that, in the opinion of the investigator, would make the subject unsuitable 
for further participation in the study. The treating investigator should contact a representative of the 
sponsor to discuss the case of any subject whose treatment has been delayed for more than 14 days 
before restarting treatment with Pemigatinib.  
Because subjects may enter the study with extensive pretreatment toxicities, these dose reduction 
rules are provided as guidelines. Individual decisions regarding dose reduction should be made 

EAU RF protocol  2018-02 
                                                                                                                                                          
Adjuvant Pemigatinib in surgically treated high-risk UC  
 
 
 
 
 
 
 
 
Final version 2.1, October 4th, 2021 
 
 
CONFIDENTIAL INFORMATION 
      Page 18 of 43 
 
 
using clinical judgment and in consultation with the sponsor's medical monitor, taking into account 
relatedness of the AE to the study drug and the subject's underlying condition. Adverse events that 
have a clear alternative explanation or transient (≤ 72 hours) abnormal laboratory values without 
associated clinically significant signs or symptoms may be exempt from dose-reduction rules. In 
case of occurrence of toxicities the investigator should, if needed, treat/follow up the patient until 
the toxicity has been resolved.  
In cases where study drug should be restarted at a next lower dose, the new dose can be 9 mg on a 
continuous schedule, and then 6.5 mg, since these were dose cohorts in the INCB 54828-101 study. 
However, individual decisions regarding dose reduction and new dose level should be made using 
clinical judgment, utilizing the tablet doses available (4.5 mg and 2 mg) and in consultation with the 
representative of the study sponsor. 
 
Table. Guidelines for Interruption and Restarting of study drug: 
ADVERSE EVENT 
ACTION TAKEN 
Chemistry 
 AST and/or ALT > 5.0 ULN 
Note: in subjects with bone metastases-related 
elevation at baseline, contact the study sponsor 
to discuss clinical management and possible 
dose-reductions. 
Step 1: interrupt study drug up to 2 weeks (14 
days) until the toxicity has resolved to ≤ Grade 
1 except by approval of the medical monitor 
Step 2: If assessed as related to study drug, 
restart study drug at next lower dose; monitor 
as clinically indicated. 
Other toxicities 
Any Grade 1 or Grade 2 toxicity 
Continue study drug treatment and treat the 
toxicity; monitor as clinically indicated 
Any Grade 3 toxicity, if clinically significant 
and not manageable by supportive care 
Step 1: interrupt study drug up to 2 weeks (14 
days) until the toxicity has resolved to ≤ Grade 
1 except by approval of the medical monitor 
Step 2: If assessed as related to study drug, 
restart study drug at next lower dose; monitor 
as clinically indicated. 
Any recurrent Grade 3 toxicity after 2 dose 
reductions 
Discontinue study drug administration.  
Any Grade 4 toxicity 
Discontinue study drug administration. 

EAU RF protocol  2018-02 
                                                                                                                                                          
Adjuvant Pemigatinib in surgically treated high-risk UC  
 
 
 
 
 
 
 
 
Final version 2.1, October 4th, 2021 
 
 
CONFIDENTIAL INFORMATION 
      Page 19 of 43 
 
 
4.3.7 Management of Hyperphosphatemia and Serous Retinal Detachment 
Table: Recommended Approach for Hyperphosphatemia management:
 
 
Table: Recommended Approach for Serous Retinal Detachment* 
RETINAL DETACHMENT  
ACTION TAKEN  
Mild and moderate  
Monitor with ophthalmology examination  
Mild and moderate with Worsening Vision  
Interrupt study drug administration until the toxicity 
has resolved or vision improved  
Worsening  
Interrupt study drug administration until the toxicity 
has resolved to mild/moderate  
Severe (Grade 3)  
Interrupt study drug administration until the toxicity 
has resolved to mild/moderate  
*participants should be monitored for signs and symptoms of serous retinal detachment, and the retina should be 
assessed with optical coherence tomography 
 
 
4.3.8 Criteria for permanent discontinuation of study drug 
The occurrence of unacceptable toxicity not caused by the underlying malignancy will be presumed 
to be related to study drug treatment and will require that the study drug be permanently 
discontinued. Unacceptable toxicity is defined as follows:  
 Occurrence of an AE that is related to treatment with the study drug that, in the judgment of the 
investigator or the sponsor's medical monitor, compromises the subject's ability to continue 
study-specific procedures or is considered to be not in the subject's best interest.  
 An AE requiring more than 2 dose reductions, if below the minimal biologically active dose of 

EAU RF protocol  2018-02 
                                                                                                                                                          
Adjuvant Pemigatinib in surgically treated high-risk UC  
 
 
 
 
 
 
 
 
Final version 2.1, October 4th, 2021 
 
 
CONFIDENTIAL INFORMATION 
      Page 20 of 43 
 
 
Pemigatinib.  
 Persistent AE requiring a interruption of therapy for more than 21 days unless a greater period 
of interruption has been approved by the sponsor.  
 Increase in QT/QTc to > 500 milliseconds or to > 60 milliseconds over baseline.  
 
4.4 During Treatment- & Follow-Up Procedures 
 
4.4.1 Concomitant Medication 
Concomitant medication has to be documented during the treatment phase. In case of existing possible 
treatment related adverse events after the treatment phase concomitant medication documentation has 
to be continued. During the study, other treatments or the administration of other drugs for the 
treatment of MIBC are not permitted. Any other non-experimental drug(s) in treatment for other 
indications are permitted if they are not prohibited (as indicated below), provided they are recorded 
in the eCRF.   
 
Restricted medications: 
The use of mild or moderate CYP3A4 inhibitors or inducers should involve careful monitoring. The 
pH level of stomach acid impacts the absorption of Pemigatinib. As a result, limited use of proton 
pump inhibitors or antacids while on study is recommended. Use of calcium-based phosphate-binding 
medications while on study is cautioned due to a concern for soft tissue mineralization. 
Close clinical surveillance is recommended when pemigatinib is administered with medicinal 
products containing P-gp or OCT2 / MATE1 substrates. 
 
Prohibited medications: 
The following medications and measures are prohibited: 
 The concomitant administration of potent CYP3A4 inhibitors and inducers (Appendix 5) is 
prohibited. Based on the low overall bioavailability of topical ketoconazole, there are no 
restrictions in its use. 
 Any concomitant use of a selective FGFR inhibitor is prohibited. 
 Investigational study drug for any indication is prohibited. 
 Use of any anticancer medications other than the study medication from 21 days before Day 1 is 
prohibited. 
 
4.4.2 Other During Treatment Examinations 
The investigator or qualified designee will obtain results of WHO performance status, ECG, 
opthalmological-, laboratory- and radiological tests as described in the flowchart (Appendix 6). 
 
4.4.3 Relapse or Progression 
All types of relapse will be included i.e. local, regional and distant metastasis as well as second 
primary tumor of the upper urinary tract. In addition, all deaths occurring without prior 
documentation of tumor relapse will be considered as an event. Any new primary cancer will not be 
considered as relapse and should be reported as SAE. All relapses must be documented by 
radiological evidence or biopsy, as determined by the investigator. Suspicion of relapse based on 
physical examination findings or laboratory signs must be confirmed by radiological examination 

EAU RF protocol  2018-02 
                                                                                                                                                          
Adjuvant Pemigatinib in surgically treated high-risk UC  
 
 
 
 
 
 
 
 
Final version 2.1, October 4th, 2021 
 
 
CONFIDENTIAL INFORMATION 
      Page 21 of 43 
 
 
and/or biopsy. Equivocal findings on standard radiological imaging should be confirmed by 
repeated examinations or cytology/histology or other imaging techniques. The date of relapse or 
progression as indicated by the date of radiology or biopsy as confirmed by the investigator, will be 
used as the timepoint of relapse or progression. At disease relapse or progression, a biopsy and 
subsequent genomic sequencing at the sponsors central laboratory is recommended after written 
informed consent of the patient.  
 
4.4.4 Subsequent Anti-Cancer Therapy Status 
The investigator or qualified designee will review all new anti-neoplastic therapy initiated after the 
last dose of trial treatment. If a participant initiates a new anti-cancer therapy within 30 days after 
the last dose of trial treatment, the 30 day Safety Follow-up visit must occur before the first dose of 
the new therapy. Once new anti-cancer therapy has been initiated the participant will move into 
survival follow-up.  
 
4.4.5 Adverse Events 
The investigator or qualified designee will report all adverse events and serious adverse events as 
indicated in chapter 6. 
 
4.5 Pregnancy 
Patients or partners of patients who become pregnant during the study treatment phase must not 
receive additional doses of study treatment but may continue other study procedures at the 
discretion of the investigator. 
The investigator, or his/her designee, will collect pregnancy information on any patient or partner of 
the patient who becomes pregnant while participating in this study i.e. from signature of informed 
consent till 3 months after the last study treatment.The investigator, or his/her designee, will record 
pregnancy information on the Pregnancy Report Form and submit it to the Sponsor within 24 hours 
of learning of a patient’s or partner of patient’s pregnancy. The pregnancy will be followed to 
determine the outcome. At the end of the pregnancy, whether that be full-term or prematurely, 
information on the status of the mother and child will be forwarded to the Sponsor. Generally, 
follow-up will be no longer than 6 to 8 weeks following the estimated delivery date.  
While pregnancy itself is not considered an AE or SAE, any pregnancy complication or elective 
termination of a pregnancy for medical reasons will be recorded and followed as an AE or a SAE, 
as described in Section 6.1 and 6.2. 
A spontaneous abortion is always considered to be a SAE and will be reported as described in 
Section 6.2. Furthermore, any SAE occurring as a result of a post-study pregnancy AND considered 
reasonably related in time to the investigational product by the investigator, will be reported to the 
Sponsor as described in Section 6.3. While the investigator is not obligated to actively seek this 
information from former study participants, he/she may learn of a pregnancy through spontaneous 
reporting. 
 
4.6 Premature Termination of the Study 
 
For reasonable cause, the Sponsor, may terminate this study provided a written notice is submitted 
at a reasonable time in advance of intended termination. 
 

EAU RF protocol  2018-02 
                                                                                                                                                          
Adjuvant Pemigatinib in surgically treated high-risk UC  
 
 
 
 
 
 
 
 
Final version 2.1, October 4th, 2021 
 
 
CONFIDENTIAL INFORMATION 
      Page 22 of 43 
 
 
 
5. PATIENT SELECTION & WITHDRAWAL CRITERIA 
 
5.1 Study Population 
 
A total of 56 patients with FGFR alterations as assessed by a centralized Foundation Medicine test 
(Foundation One) will be eligible to start Pemigatinib after providing their informed consent if they 
meet all of the following inclusion criteria. 
 
5.2 Inclusion Criteria 
 
1. Men and woman, aged 18 years or older with histological evidence of pT3-4 and/or pN1-3 
urothelial cancer (UC) of the urinary bladder or upper urinary tract after radical cystectomy / 
radical nephroureterectomy. Patients with mixed histologies are required to have a dominant 
(i.e. at least 50%) urothelial cell carcinoma pattern. 
2. Previous administration of at least 2-3 cycles of neoadjuvant cisplatin-based chemotherapy OR, 
if neoadjuvant chemotherapy was not administered, ineligibility to receive cisplatin-based 
adjuvant chemotherapy based on Galsky’s criteria, that include at least one of the following: (1) 
WHO performance status ≥ 2 and/or (2) creatinine-clearance < 60 ml/min and/or (3) CTCAE Gr 
≥ 2 hearing loss and/or (4) CTCAE Gr ≥ 2 neuropathy [23]. 
3. Evidence of FGFR3 alterations (mutations or gene fusions as specified in protocol) as assessed 
by a centralized Foundation Medicine test (Foundation One CDx assay). 
A list of the allowed FGFR alterations is provided below. 
 
GENE 
ALTERATION 
FGFR3 
R248C 
FGFR3 
S249C 
FGFR3 
G370C 
FGFR3 
S371C 
FGFR3 
Y373C 
FGFR3 
G380R 
FGFR3 
G380E 
FGFR3 
A391E 
FGFR3 
 R399C 
FGFR3 
 S433C 
FGFR3 
D641N 
FGFR3 
K650M 
FGFR3 
K650E 
FGFR3 
K650Q 
FGFR3 
K650T 
FGFR3 
K650N 
FGFR3 
Novel FGFR3 fusion (with partner specified) 
FGFR3 
FGFR3-BAIAP2L1  
FGFR3 
FGFR3-IGH 
FGFR3 
FGFR3-TACC3 
FGFR3 
FGFR3-WHSC1 
 
4. Recovered with no evidence of disease confirmed by radiological images, prior to start of 
adjuvant therapy within 13 weeks after radical surgery. 
5. WHO performance status of 0, 1 or 2. 

EAU RF protocol  2018-02 
                                                                                                                                                          
Adjuvant Pemigatinib in surgically treated high-risk UC  
 
 
 
 
 
 
 
 
Final version 2.1, October 4th, 2021 
 
 
CONFIDENTIAL INFORMATION 
      Page 23 of 43 
 
 
6. Willingness to avoid pregnancy or fathering children. If the patient is male, he must use a 
condom during sexual intercourse during the treatment period and 240 days thereafter (120 days 
to eliminate study treatment and 120 days spermatogenesis cycle) plus partner use of a 
contraceptive method with a failure rate of <1% per year (See Appendix 1). If the patient is 
female, and of childbearing potential, she must practice adequate contraception (Appendix 1) 
for 30 days prior to administration of study treatment, have a negative pregnancy test and 
continue such precautions during the study treatment period and for 150 days after the last study 
treatment (120 days to eliminate study treatment and 30 days menstruation cycle) (See 
Appendix 1 for standards of adequate contraceptive methods). 
7. Written informed consent for screening of tumor tissue and if evidence of FGFR alterations 
written informed consent for the start of the complete study. 
 
5.3 Exclusion Criteria 
 
Patients with any of the following exclusion criteria will NOT be eligible for the study: 
 
1. Any previous receipt of a selective FGFR inhibitor. 
2. Presence of primary CIS only. 
3. Presence of another malignancy in the 3 years before enrolment except for basal cell 
carcinoma or squamous cell carcinoma of the skin, cis of cervix, localised prostate cancer in 
active surveillance or other non invasive or other indolent malignancy that has undergone 
potentially curative therapy. 
4. Presence of pregnancy or lactation or not willing to avoid pregnancy or fathering children. 
5. Distant metastases (M1 disease) or presence of radiological evidence of disease at baseline. 
6. Treatment with other investigational drugs, receipt of anticancer medications (except for 
neoadjuvant cisplatin-based chemotherapy, see second inclusion criterion) or radiotherapy of 
the bladder or upper urinary tract prior to- or after radical surgery. 
7. Use of any potent CYP3A4 inhibitors or inducers within 14 days or 5 half lives (whichever is 
longer) before the first dose of study Tx. 
8. Abnormal laboratory parameters: 
i. 
Total bilirubin ≥ 1.5 × upper limit of normal (ULN; ≥ 2.5 × ULN if Gilbert syndrome). 
ii. 
AST and/or ALT > 2.5 × ULN  
iii. 
Creatinine clearance ≤ 30 mL/min based on Cockroft-Gault. 
iv. 
Serum phosphate > institutional ULN. 
v. 
Serum calcium outside of the institutional normal range or serum albumin-corrected 
calcium outside of the institutional normal range when serum albumin is outside of 
the institutional normal range.  
9. History of human immunodeficiency virus infection or active tuberculosis infection. 
10. Diagnosis of immunodeficiency or receiving chronic systemic steroid therapy (exceeding > 
10 mg daily of prednison equivalent; inhalation steroids are permitted). 
11. Evidence of hepatitis B virus or hepatitis C virus active infection or risk of reactivation. 
12. Severe hepatic impairment . 
13. Known prior severe hypersensitivity to investigational product or its excipients. 

EAU RF protocol  2018-02 
                                                                                                                                                          
Adjuvant Pemigatinib in surgically treated high-risk UC  
 
 
 
 
 
 
 
 
Final version 2.1, October 4th, 2021 
 
 
CONFIDENTIAL INFORMATION 
      Page 24 of 43 
 
 
14. History of clinically significant or uncontrolled cardiac disease, including unstable angina, 
acute myocardial infarction within 6 months from enrollment, NYHA Class III or IV 
(Appendix 4).  
15. Current evidence of corneal disorder/keratopathy (including but not limited to bullous/band 
keratopathy, corneal abrasion, inflammation/ulceration, keratoconjunctivitis, etc) or retinal 
disorder (including but not limited to, central serous retinopathy, macular/retinal 
degeneration, diabetic retino-pathy, retinal detachment, etc) as confirmed by ophthalmologic 
examination. 
16. Any condition that would, in the investigator's judgment, interfere with full participation in 
the study, including administration of study drug and attending the required study visits. 
 
5.4 Patient Withdrawal and Early Dropouts (off study) 
 
In the patient informed consent form the patients will be informed that they have the right to withdraw 
from the study at any time without affecting their subsequent care and may be withdrawn at the 
investigator’s discretion at any time. In the event that the patient drops out, the investigator will, if 
possible, indicate the reason for withdrawal. Reasonable effort will be made to contact any patient 
lost to follow up during the course of the study in order to complete assessments and retrieve any 
outstanding data. Patients withdrawn from the trial will not be replaced. 
 
Off study criteria: 
 When the investigator considers it in the best interest of the patient that he/she will be 
withdrawn 
 Patient or legal representative request withdrawal of informed consent  
 Lost to follow up or administrative reasons 
 Non-compliance with study treatment or procedure requirements. 
 Study termination by ethical- or health authorities or the Sponsor. 
 Others, only applicable after consultation with the sponsors study monitor. 
 
Participants who discontinue study treatment prior to completion of the treatment period should be 
encouraged to continue to be followed for all remaining study visits. 
 
When a participant discontinues/withdraws from participation in the trial, if possible, all applicable 
activities scheduled for the final study visit should be performed at the time of discontinuation. Any 
adverse events which are present at the time of discontinuation/withdrawal should be followed in 
accordance with the safety requirements outlined in chapter 6 - Adverse Events. 
If the patient discontinues study treatment and actively withdraws consent for collection of follow-
up data (safety follow-up or disease assessment), then no additional data collection should occur; 
however, patients will have the option of withdrawing consent for study treatment but continuing in 
the follow-up period of the study for safety/efficacy assessments. 
 
Notes:  
 Patients who experience unacceptable study drug related adverse events should stop treatment 
with the study drug. These patients continue follow up for disease status and survival. 

EAU RF protocol  2018-02 
                                                                                                                                                          
Adjuvant Pemigatinib in surgically treated high-risk UC  
 
 
 
 
 
 
 
 
Final version 2.1, October 4th, 2021 
 
 
CONFIDENTIAL INFORMATION 
      Page 25 of 43 
 
 
 Patients who develop a relapse or metastases of disease stop study drug treatment and they 
are asked to consent with biopsy and subsequent genomic sequencing after relapse or 
metastases, whereafter follow up for survival only is continued. 
 Patients who become pregnant should stop study drug treatment and should be followed for 
the outcome of pregnancy and survival. 
 
 
6. REPORTING ADVERSE EVENTS 
 
6.1 Adverse Events (AE’s) 
An adverse event is any undesirable clinical occurrence in a patient whether it is considered to be 
drug related or not. The observed or volunteered adverse events regardless of suspected causal 
relationship to the study treatment will be recorded on the adverse event page of the eCRF. An 
adverse event is classified by the investigator as mild (1), moderate (2), severe (3) life threatening 
(4) or death (5) according to the National Cancer Institute Common Terminology Criteria for 
Adverse Events v4.0 (CTCAE, Appendix 2).  
Events involving adverse treatment reactions, illness with onset during the study, or exacerbations 
of pre-existing illness should be recorded. Objective test finding (e.g. laboratory results) that need 
treatment should also be recorded. 
Note that the following examples of adverse events do not need to be recorded: 
• Medical or surgical procedures (e.g. endoscopy, appendectomy); the condition that leads to the 
procedure is an AE. 
• Hospitalisation for elective treatment of a pre-existing condition (known/diagnosed prior to 
informed consent signature) that did not worsen from baseline. 
• Situations where an untoward medical occurrence did not occur (e.g. social and/or convenience 
admission to a hospital, admission for routine examination). 
• Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present or detected at 
the start of the study that do not worsen. 
• The disease/disorder being studied, or expected relapse, progression, signs, or symptoms of the 
disease/disorder being studied, unless more severe than expected for the patient’s condition. 
 
An example of events which are to be recorded in the medical history section of the eCRF and not as 
an AE is eg. pre-existing conditions or signs and/or symptoms present in a patient prior to the start of 
the study (i.e. prior to the first study product administration). 
The investigator should also provide information on the duration (start and stop date), relation to 
study treatment, start of concomitant therapy and outcome of the adverse event. Follow up of the 
adverse event after therapy discontinuation, is required if the adverse event or its sequelae persist. 
Follow up is required until the event or its sequelae resolve or stabilize at a level acceptable to the 
investigator. Adverse event information will be collected from the start of drug treatment up to the 
visit 30-35 days after stop of drug treatment or longer if drug related adverse events have not 
resolved or not returned to baseline, whichever is longest. A representative of the Sponsor shall 
consider all adverse events and, if required, shall report them to the appropriate authorities. 
 
6.2 Serious Adverse Events (SAE’s) 
A serious adverse event is any untoward medical occurrence that at any dose: 

EAU RF protocol  2018-02 
                                                                                                                                                          
Adjuvant Pemigatinib in surgically treated high-risk UC  
 
 
 
 
 
 
 
 
Final version 2.1, October 4th, 2021 
 
 
CONFIDENTIAL INFORMATION 
      Page 26 of 43 
 
 
- results in death 
- is life-threatening 
- requires inpatient hospitalisation or prolongation of existing hospitalization (except for 
elective hospitalization for a pre-existing condition that did not worsen from baseline; See 
6.1) 
- results in persistent or significant disability / incapacity or 
- is a congenital anomaly/birth defect. 
If, as a result of an adverse event during a clinical investigation, a patient has to be hospitalised, or 
their hospitalisation is unduly prolonged because of potential disability or danger to life or because 
an intervention has been necessitated or the event is terminal, the adverse event is regarded as 
serious. For example, if – according to the investigator - an adverse event causes foetal distress, 
foetal death or a congenital anomaly or malignancy results from the use of the drug during a clinical 
investigation, this would be processed as a serious adverse event. 
All serious adverse events which occur from the start of study treatment up to the Safety follow up 
visit 30-35 days after EOT visit whether or not considered related to the treatment, must be reported 
immediately (within one day of the investigator becoming aware of the adverse event) by sending a 
completed Serious Adverse Event Report Form by e-mail or fax to EAU RF representatives:  
ClinicalTrial@phast.it with a copy to the recipient at EAU RF: RFsafety@uroweb.org. Serious adverse 
events related to either study participation or related to study treatment should be reported 
throughout the entire study period.  
An event which is part of the natural course of the disease under study (i.e., disease relapse or 
progression) is captured as an efficacy measure; therefore it does not need to be reported as a SAE. 
Progression/relapse of the tumor will be recorded in the clinical assessments in the eCRF. Death due 
to a progressive disease is to be recorded on a specific form in the eCRF but not as a SAE. 
However, if relapse or progression of the underlying disease is more severe than what would normally 
be expected for the patient, or if the investigator considers that there was a causal relationship between 
study drug treatment or protocol design/procedures and the disease 
progression/relapse, then this must be reported as a SAE. Any new cancer (non-related to the cancer 
under study) must be reported as an SAE. 
A representative of the Sponsor will report SAE’s to the IRB/IEC that approved the protocol and to 
the regulatory authorities via the annual general progress report or development safety update 
reports (DSURs). (See also 8.4) 
 
6.3 Suspected Unexpected Serious Adverse Reactions (SUSAR’s) 
Suspected unexpected adverse reactions are SAE’s considered to be related to study treatment, of 
which the nature, or severity, is not consistent with the information in the Investigators drug 
Brochure (IB). 
A representative of the Sponsor will report (expedited) all SUSARs to the investigators, competent 
authorities and IEC’s. The expedited reporting will occur within the per law defined time intervals 
which is currently not later than 15 days after the Sponsor has first knowledge of the adverse 
reactions. For fatal or life threatening cases the term is currently a maximum of 7 days for a 
preliminary report, with another 8 days for completion of the report.  
 
 

EAU RF protocol  2018-02 
                                                                                                                                                          
Adjuvant Pemigatinib in surgically treated high-risk UC  
 
 
 
 
 
 
 
 
Final version 2.1, October 4th, 2021 
 
 
CONFIDENTIAL INFORMATION 
      Page 27 of 43 
 
 
7. STATISTICAL CONSIDERATIONS 
 
7.1 Patient Accrual, Study Duration and Calculation of Patient Numbers 
 
The recruitment period will be 2 years and patients will be followed for an additional 2 years or 
until relapse or progression. 2-Year relapse-free survival (RFS) rate is the primary endpoint. No 
interim analyses are planned. Patients will be consecutively molecularly screened and enrolled into 
the study. It is expected that about 35% of the total screened patients will be eligible and will be 
enrolled in this study to receive Pemigatinib treatment. Treatment will be continued for a maximum 
period of 12 months or until the evidence of disease relapse or unacceptable toxicity development. 
The assumption is that treatment with Pemigatinib will result in a significant higher 2-year RFS rate 
at 2 years of 45% RFS compared to the reported 30% RFS at 2 years in bladder cancer patients [3].  
 
Statistical Power Calculations: 
In an exact single-stage phase II design [24] with power: 0.80; one-sided alpha: 0.10; H0: 2-year 
RFS: 30%; H1: 2-year RFS: 45% and follow-up duration of 2 years, the total number of eligible and 
treated patients needed to be enrolled is 50. Patients who withdraw from the study before 
completing the study period of 2 years, cannot be included in the calculation of the 2-year RFS rate. 
We estimate that   ~15% of the patients will be withdrawn. Therefore, we need a total of 56 patients 
enrolled. Cut-off to reject the alternative hypothesis H1 is a total of 20 or more patients who 
experience relapse or progression at or before 2 years of study follow up. 
 
A total of 56 patients needed in this phase II trial is corresponding to approximately 150 patients 
needed for molecular pre-screening. The primary analysis includes the planned analysis of the 
primary endpoint 2-year RFS rate which will be analyzed at the 2-years follow-up time point. RFS 
is defined as the time from the date of start of treatment until disease relapse or progression by 
investigator determination, or death due to any cause, whichever occurs first. See also 4.4.3. 
 
7.2 Efficacy Analysis Population 
 
The intention to treat (ITT) population will serve as the population for the primary and key 
secondary efficacy analyses. For the secondary efficacy analyses, all enrolled and eligible patients 
who will receive at least one dose of the study drug will be included.  
 
7.3 Safety Analysis Population 
 
The safety analysis population will be represented by all patients included in this study, including 
bladder cancer patients and upper tract tumor patients, and will be used for the analysis of safety 
data in this study. The population consists of all randomized participants who received at least 1 
dose of study treatment.  
 
7.4 Statistical Analysis 
 
7.4.1 Demographics, Safety and Tolerability and Biomarkers Analysis 
Missing data will not be replaced. Descriptive statistics, e.g. mean, standard deviation, median, 
range, frequency distributions will be used to characterize patient characteristics, demographics and 

EAU RF protocol  2018-02 
                                                                                                                                                          
Adjuvant Pemigatinib in surgically treated high-risk UC  
 
 
 
 
 
 
 
 
Final version 2.1, October 4th, 2021 
 
 
CONFIDENTIAL INFORMATION 
      Page 28 of 43 
 
 
baseline measurements of the patient population. For each patient enrolled, the reason for 
discontinuation (e.g. patient decision, urologists decision, lack of efficacy, adverse events) should 
be clarified. The description of the reasons for discontinuation will be performed. Descriptive 
statistics and frequency distributions as appropriate will be presented to summarize the toxicity 
profile. Safety and tolerability will be assessed by clinical review of all relevant parameters 
including AEs, SAEs, SUSARs and laboratory tests as described above. The incidence and severity 
of all serious and non-serious adverse events will be tabulated as well as the treatment related 
toxicity > grade 2. At least one laboratory or vital sign measurement obtained subsequent to at least 
one dose of study treatment is required for inclusion in the analysis of each specific parameter. To 
assess change from baseline, a baseline measurement is also required.  
A summary of tumor-specific gene alterations and gene expression profiles and their correlation to 
RFS and OS with Pemigatinib treatment will also be prepared. 
 
7.4.2 Relapse Free Survival Analysis and 2 year RFS rate 
Relapse free survival is defined as the time from the date of start of study treatment until disease 
relapse or progression by Investigator determination, or death due to any cause, whichever occurs 
first. Relapse free survival will be analyzed and graphically presented by the Kaplan-Meier method. 
The percentage of patients with relapse free survival at 2 years will be calculated with its 95% 
Confidence Interval. 
 
7.4.3 Overall Survival Analysis 
Overall Survival (OS) is defined as the time from the date of start of study treatment to death due to 
any cause. Participants without documented death at the time of analysis will be censored at the 
date of the last follow-up. Overall survival will be analyzed and graphically presented by the 
Kaplan-Meier method. The percentage of patients who survive at 2 years will be calculated with its 
95% Confidence Interval. 
 
 
8. ETHICAL AND ADMINISTRATIVE CONSIDERATIONS; PUBLICATION 
 
8.1 Ethical and Regulatory Considerations 
 
This study will be performed in accordance with ethical principles that originate in the Declaration 
of Helsinki (see for the most recent version: www.wma.net) and conducted in adherence to the 
study Protocol; GCP; and local regulatory requirements as applicable to the study locations. 
 
Prior to the start of the study, approval from the IRB/IEC in accordance with applicable country-
specific regulatory requirements will be obtained. The processing of the personal data of patients 
taking part in this study, and in particular regarding data related to consent, shall comply with the 
local law on the privacy and, for the European Union, with the General Data Protection Regulation 
(GDPR) as of May 2018.  
 
The genomic sequencing tests are provided by Roche Italy and Roche Germany in collaboration 
with Foundation Medicine. Roche and Foundation Medicine located in Germany will receive the 
pseudonomized patient details and tissue samples will be send to Foundation Medicine GmbH by 

EAU RF protocol  2018-02 
                                                                                                                                                          
Adjuvant Pemigatinib in surgically treated high-risk UC  
 
 
 
 
 
 
 
 
Final version 2.1, October 4th, 2021 
 
 
CONFIDENTIAL INFORMATION 
      Page 29 of 43 
 
 
clinicians and/or pathologists of the participating hospitals for genomic sequencing. The resulting 
data will subsequently be made accessible (always pseudonomized) to Foundation Medicine Inc. in 
USA for the analysis of the acquired genomic data, the correspondence and the drafting of the 
report that will be returned to the clinician and/or pathologists of the participating hospitals.. 
Patients will explicitly have to give consent to the transfer of their pseudonymised data to the US. 
Roche and Foundation Medicine will retain the personal pseudonomised data and destroy these data 
after a period of 10 years. Foundation Medicine will return any unused tissue samples to the 
hospitals pathologists. Patients can withdraw their consent and obtain cancellation of personal data 
shared with the aforementioned companies. However, Foundation Medicine Inc, USA has the 
possibility to treat and use some data in a completely anonymous form, even if the consent is 
withdrawn by the patient. 
Eligible patients will be fully informed by the Principal Investigator (PI), the local investigator 
and/or the local research coordinator and his research staff, whatever is applicable, about the study 
and asked to participate. The patient will receive a patient information sheet and will have ample 
opportunity to ask any questions he/she might have. He/she will have sufficient time to consider the 
study’s implications before deciding to participate in the study. Patient’s consent will be noted on 
an informed consent form (ICF). 
 
If during the study the patient for whatever reason no longer wishes to participate he/she can 
withdraw his/her consent at any time. Study medication will then be stopped and further treatment 
will be initiated at the discretion of the treating physician. 
Informed consent must be obtained before any study-related procedures are conducted, unless 
otherwise specified by the Protocol.  
It is the responsibility of the investigator to verify adherence to the protocol, the protection of the 
rights of the patient, the completeness, accuracy and consistency of the data to be entered in the 
eCRF and adherence to local regulations. 
 
8.2 Study Organisation & Management 
 
For this multicentre study, an initiating investigators meeting at a central location will be held to 
standardise data management procedures and resolve questions regarding protocol conduct. At the 
initiation meeting, the investigator and eventual other site study personnel will be instructed how to 
conduct the study- and data management procedures. In addition, the sites will be provided with the 
required materials by the EAU RF representatives. EAU RF’s representatives may conduct field 
data review periodically. It is the responsibility of EAU RF’s representatives to verify adherence to 
the protocol and the completeness, accuracy and consistency of the data. The investigator or a 
qualified employee will enter all relevant data into eCRF’s, in accordance with the instructions 
provided. 
 
8.3 Handling and Storage of Data and Documents 
 
Data management will be performed in a validated database via an Electronic Data Capture (EDC) 
system. The investigator and other involved site personnel will be trained in the proper use of the 
EDC system after which they will be provided with access to the EDC system so that an eCRF can 
be completed for each subject. Entries made in the eCRF must be verifiable against source 

EAU RF protocol  2018-02 
                                                                                                                                                          
Adjuvant Pemigatinib in surgically treated high-risk UC  
 
 
 
 
 
 
 
 
Final version 2.1, October 4th, 2021 
 
 
CONFIDENTIAL INFORMATION 
      Page 30 of 43 
 
 
documents; if updates to the database are not possible, any discrepancies should be explained and 
documented. The investigator will be responsible for reviewing all data and eCRF entries, and will 
sign and date the designated forms in each subject's eCRF, verifying that the information is true and 
correct. The investigator is responsible for the review and approval of all query responses.  
 
The investigator will guarantee that all team members and other persons involved in his centre will 
respect the confidentiality of any information related to the study patients. All parties involved in 
this study will maintain strict confidentiality to assure that the patients privacy is not violated. 
Likewise, the appropriate measures shall be taken to avoid  access of the study data by non-
authorised persons. Patient data will be pseudonymized before entering in the database and extracts 
of the data will be available for statistical analyses and reporting.  
 
Qualified representatives of the sponsor or its designees, study monitors, will monitor the study 
according to a predetermined plan. The investigator must allow the study monitors to review any 
study materials and subject records at each monitoring visit.  
Original subject records (e.g., hospital charts, clinical records, pathology reports, laboratory 
printouts) should be available at each study site for source document review by the sponsor  or its 
designees. Source document review is the cross checking of information recorded on eCRF’s with 
that recorded in the original subject records. It is not the purpose of source document review to 
ensure that all information in the eCRF is also recorded elsewhere in the subject’s records; the 
purpose is to help ensure that the eCRF accurately reflects information generated during the study. 
In this study, source document review of specific types of information will be conducted in all 
patients enrolled. The sponsor and/or its designee  ensure the privacy of the patient data by only 
collecting the patient data without the patient details that could identify the individual patient. The 
investigator should give the monitor access to all relevant patient data. Queries to be issued to the 
investigator will consist of questions to clarify for instance missing data, inconsistencies, illegible 
data, illegal values and items that are not clearly corrected. 
 
When all patient and visit data are received at the sponsor or its designee, all data problems have 
been resolved, all data checks and quality control checks have been performed, the study database is 
considered to be clean and can be locked. In addition, the study centre may be audited in depth for 
study quality assurance by the sponsor or its designee, and/or inspected by a national regulatory 
authority. This audit may include review of all source documents, drug records, original clinic case-
notes, some or all of the facilities used in the trial, etc. Patient confidentiality will be maintained at 
all times and consent for this will be obtained prior to entry of the patient into the clinical trial. 
 
8.4 Amendments 
 
Amendments are changes made to the study protocol, after an initial favourable opinion by the 
IRB/IEC has been given. Amendments will be notified or submitted for approval to the IRB/IEC as 
required according to local law. 
 
8.5 General Progress Report 
 
According to local requirements, the sponsor / principal investigator (PI) will submit a summary of 
the progress of the study to the IRB/IEC once a year. Information will be provided on the date of 

EAU RF protocol  2018-02 
                                                                                                                                                          
Adjuvant Pemigatinib in surgically treated high-risk UC  
 
 
 
 
 
 
 
 
Final version 2.1, October 4th, 2021 
 
 
CONFIDENTIAL INFORMATION 
      Page 31 of 43 
 
 
inclusion of the first patient, numbers of patients included and numbers of patients that have 
completed the study, Serious Adverse Events / Suspected Serious Adverse Reactions (SUSARs), 
other issues, and amendments. 
 
8.6 End of Study Report 
 
According to local requirements, the sponsor/PI will notify the IRB/IEC of the end of the study 
within a period of 8 weeks. The end of the study is defined as the last patient’s last visit. In case the 
study is ended prematurely, the sponsor / PI will notify the IRB/IEC within 15 days, indicating the 
reasons for the premature termination.  
 
Within one year after the end of the study, the sponsor / PI will submit a final study report with the 
results of the study, including any publications/abstracts of the study, to the IRB/IEC. 
 
8.7 Steering Committee 
 
A Steering Committee will be assembled, consisting of urologist / medical oncologists key opinion 
leaders in the field of genito-urinary surgery and oncology and physicians/scientists with clinical 
and methodological expertise. The Steering Committee is responsible for the assignment of 
National Coordinators. Each participating country has one National Coordinator who has been 
selected by the Steering Committee. The Steering Committee will convene once or twice a year 
during recruitment phase of the study. Meeting frequency may decrease during the follow-up phase 
of the study. 
 
8.8 Public Disclosure and Publication Policy 
 
Any formal presentation or publication of data collected from this study will be considered as a 
joint publication by the participating investigator(s) and the Steering Committee. Guidelines on 
authorship will follow the recommendations of the International Committee of Medical Journal 
Editors (ICMJE). 
 
The first publication will be based on data from all centers, analyzed as stipulated in the protocol by 
statisticians/epidemiologists acting on behalf of the sponsor. The investigators agree that they can 
present data collected at one center or a small group of centers before the full, initial publication, 
after obtaining written agreement of the sponsor on behalf of the Steering Committee. 
The sponsor must receive copies of any intended communication in advance of submission for 
publication. In order to ensure that the sponsor will be able to make comments and suggestions 
where pertinent, material for public dissemination will be submitted to the sponsor for review at 
least ninety (90) days prior to submission for publication, public dissemination, or review by a 
publication committee. 
 
Parties who wish to present or publish any data from this study can submit a formal request to the 
sponsor or the Steering Committee. After formal agreement by the sponsor the procedure as 
described above for any intended communication will need to be followed. 
 

EAU RF protocol  2018-02 
                                                                                                                                                          
Adjuvant Pemigatinib in surgically treated high-risk UC  
 
 
 
 
 
 
 
 
Final version 2.1, October 4th, 2021 
 
 
CONFIDENTIAL INFORMATION 
      Page 32 of 43 
 
 
8.9 Financing and insurance 
 
There are no special incentives or financial compensations that patients will receive through 
participation in the study. The Sponsor or its representatives will arrange a liability insurance 
/clinical trial insurance which is in accordance with GCP and local legal requirements. 
 
8.10 Risk analysis 
 
This is a phase II study with a drug that has indicated promising effects for relapse free survival in 
this high-risk group of patients who need a cystectomy or nephroureterectomy for treatment of their 
urothelial carcinoma. On the other hand, there are side effects that should be managed with dose 
reduction or stop; frequent laboratory checks or other supportive measures in consultation with a 
medical oncologist. Further, at relapse or progression, subjects will be asked to sign a consent to 
allow a biopsy of the relapse or metastases and tumor tissue to be sent to the sponsor's central 
laboratory (Foundation Medicine) for genetic sequencing. Based on the current available 
information of Pemigatinib, the risks related to the expected treatment outcome, quality and 
quantity of side effects of the study medication can be considered as acceptable. 
Benefit for the patient is that the patient is followed according to the latest standards and guidelines 
of treatment of MIBC and the patient has a chance on early detection of relapse of disease. 
 
Privacy risks are covered as much as possible by following well established procedures such as 
pseudonymization of the data which are entered in the web based eCRF. For accidents where the 
confidentiality of privacy may be at risk, the EAU-RF has taken a privacy insurance for  the entire 
duration of the study. 
 
Another risk is that, although a feasibility questionnaire that was performed amongst the potential 
participants prior to the finalisation of the study protocol indicated that the number of 56 patients 
can be reached within the specified timeframe of 2 years, the recruitment can stay behind 
expectations. To avoid such a risk, the recruitment will be closely monitored. If recruitment is 
clearly behind expectations, the Steering Committee in mutual agreement with the sponsor may 
decide to ask more European centres interested to participate in this study or prolong the 
recruitment period. 
 
 
9 REFERENCES 
 
1. Siegel R.L., Millder K.D., Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018; 68:7-
30. 
2. EAU Guidelines. http://uroweb.org/guideline/bladdercancermuscle-invasive-and-metastatic. 
3. P.I. Karakiewicz, S.F. Shariat, G.S. Palapattu, A.E. Gilad, et al. Nomogram for Predicting 
Disease Recurrence After Radical Cystectomy for Transitional Cell Carcinoma of the 
Bladder. J. Urol. 2006; 176: 1354-1362. 
4. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy 
in invasive bladder cancer: update of a systematic review and meta-analysis of individual 

EAU RF protocol  2018-02 
                                                                                                                                                          
Adjuvant Pemigatinib in surgically treated high-risk UC  
 
 
 
 
 
 
 
 
Final version 2.1, October 4th, 2021 
 
 
CONFIDENTIAL INFORMATION 
      Page 33 of 43 
 
 
patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol. 2005 
Aug;48(2):202-5; discussion 205-6. 
5. H.S. Kim, C.W. Jeong, C. Kwak, H.H. Kim and J.H. Ku. Pathological T0 Following 
Cisplatin-Based Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A 
Network Meta-analysis. Clin Cancer Res 2016; 22(5) 1086-1094. 
6. van de Putte E.E.F., Mertens L.S., Meijer R.P., van der Heijden M.S., Bex A., van der Poel 
H.G., et al. Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: 
efficacy and safety compared with classic MVAC and gemcitabine/cisplatin. World J Urol. 
(2016) 34:157–62. 
7. Choueiri T.K., Jacobus S., Bellmunt J., Qu A., Appleman L.J., Tretter C., et al. Neoadjuvant 
dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support 
in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin 
Oncol. (2014) 32:1889–94.  
8. Plimack E.R., Hoffman-Censits J.H., Viterbo R., Trabulsi E.J., Ross E.A., Greenberg R.E., 
et al. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective and 
efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter 
phase II study with molecular correlates of response and toxicity. J Clin Oncol. (2014) 
32:1895–901. 
9. Bhindi B., Frank I., Mason R.J., et al. Oncologic Outcomes for Patients with Residual 
Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched 
Analysis. Eur Urol. 2017; 72(5) 660-664. 
10. Mertens L.S., Meijer R.P., Meinhardt W., et al. Occult lymph node metastases in patients 
with carcinoma invading bladder muscle: incidence after neoadjuvant chemotherapy and 
cystectomy vs after cystectomy alone. BJU Int 2014; 114:67-74. 
11. Kassouf W, Agarwal PK, Grossman HB, et al. Outcome of patients with bladder cancer with 
pN+ disease after preoperative chemotherapy and radical cystectomy. Urology 2009; 
73:147-52. 
12. Leow JJ, Martin-Doyle W, Rajagopal PS, et al. Adjuvant chemotherapy for invasive bladder 
cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol 
2014; 66:42-5. 
13. R. Millikan, C.Dinney, D. Swanson, P. Sweeney, J.Y. Ro, T.L. Smith, D. Williams, C. 
Logothetis. Integrated Therapy for Locally Advanced Bladder Cancer: Final Report of a 
Randomized Trial of Cystectomy Plus Adjuvant M-VAC Versus Cystectomy With Both 
Preoperative and Postoperative M-VAC. J Clin Oncol 2001; 19: 4005-4013. 
14. Hermans T.J.N., Voskuilen C.S., Deelen M., Mertens L.S., Horenblas S., Meijer R.P., 
Boormans J.L., Aben K.K., van der Heijden M.S., Pos F.J., de Wit R., Beerepoot L.V., 
Verhoeven R.H.A., van Rhijn B.W.G. Superior efficacy of neoadjuvant chemotherapy and 
radical cystectomy in cT3-4aN0M0 compared to cT2N0M0 bladder cancer. Int. J of Cancer 
2018; online Aug 2018. https://doi.org/10.1002/ijc.31833. 
15. J. Bellmunt, R. de Wit, D.J. Vaughn, et al. Pembrolizumab as Second-Line Therapy for 
Advanced Urothelial Carcinoma. N Engl J Med 2017; 376:1015-1026. 
16. A. Necchi, A. Anichini, D. Raggi, A. Briganti, et al. Pembrolizumab as Neoadjuvant 
Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder 
Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. J Clin Oncol 2018; 36: 
1-11. 

EAU RF protocol  2018-02 
                                                                                                                                                          
Adjuvant Pemigatinib in surgically treated high-risk UC  
 
 
 
 
 
 
 
 
Final version 2.1, October 4th, 2021 
 
 
CONFIDENTIAL INFORMATION 
      Page 34 of 43 
 
 
17. B. Lombardi, P. Ashford, et al. Unique signalling connectivity of FGFR3-TACC3 
oncoprotein revealed by quantitative phosphoproteomics and differential network analysis. 
Oncotarget. 2017 Oct 25;8(61):102898-102911. 
18. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of 
urothelial bladder carcinoma. Nature. 2014 Mar 20; 507(7492): 315–322. 
19. Tabernero J, Bahleda R, Dienstmann R, et al. Phase I dose-escalation study of JNJ-
42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced 
solid tumors. J Clin Oncol 2015;33:3401-3408. 
20. Necchi A., Perez Gracia J.L., Loriot Y., Witjes W., Montorsi F., Bjartell A., Shariat S.F. 
Evaluating safety and efficacy of INCB054828 as adjuvant therapy for molecularly-selected, 
high-risk patients with urothelial carcinoma. Poster at EAU annual congress 2018. 
Copenhagen. Eur Urol Suppl 2018; 17(2).  https://doi.org/10.1016/S1569-9056(18)31635-X 
21. Global Investigator’s Brochure INCB054828 (Pemigatinib) V7, 15 Jan. 2021. 
22. Witjes J.A., Lebret T, Compérat E.M. et al. Updated 2016 EAU Guidelines on Muscle-
invasive and Metastatic Bladder cancer. European Urology 71 (2017), 462-475. 
23. M.D. Galsky, N.M. Hahn, J. Rosenberg, G. Sonpavde, T. Hutson, W.K. Oh, et al. Treatment 
of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy. J 
Clin Oncol 2011;29 (17); 2432-2438. 
24.  R.P.A'Hern. Sample size tables for exact single-stage phase II designs. Statist. Med. 2001; 
20:859-866. 
25. Oken MM, Creech RH, Tormey DC, et al (1982). "Toxicity and response criteria of the 
Eastern Cooperative Oncology Group". Am. J. Clin. Oncol. 5 (6): 649–55. 

EAU RF protocol  2018-02 
                                                                                                                                                          
Adjuvant Pemigatinib in surgically treated high-risk UC  
 
 
 
 
 
 
 
 
Final version 2.1, October 4th, 2021 
 
 
CONFIDENTIAL INFORMATION 
      Page 35 of 43 
 
 
Appendix 1 Contraceptive Guidance and Pregnancy Testing 
 
Woman of Childbearing Potential (WOCBP) 
 
A woman is considered fertile following menarche and until becoming post-menopausal unless 
permanently sterile (see below)  
 
Women in the following categories are not considered WOCBP: 
● 
Premenarchal 
● 
Premenopausal female with 1 of the following: 
○ Documented hysterectomy 
○ Documented bilateral salpingectomy 
○ Documented bilateral oophorectomy 
Note:  Documentation can come from the site personnel’s review of the participant’s 
medical records, medical examination, or medical history interview. 
● 
Postmenopausal female 
○ A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause.  
▪ 
A high follicle stimulating hormone (FSH) level in the postmenopausal range may be 
used to confirm a postmenopausal state in women not using hormonal contraception or 
hormonal replacement therapy (HRT). However, in the absence of 12 months of 
amenorrhea, confirmation with two FSH measurements in the postmenopausal range is 
required.  
○ Females on HRT and whose menopausal status is in doubt will be required to use one of the 
non-hormonal highly effective contraception methods if they wish to continue their HRT 
during the study. Otherwise, they must discontinue HRT to allow confirmation of 
postmenopausal status before study enrollment. 
 
Contraception Requirements 
 
Male Participants: 
Male participants with female partners of childbearing potential are eligible to participate if they 
agree to one of the following during the treatment phase and 240 days thereafter:  
● 
Be abstinent from penile-vaginal intercourse as their usual and preferred lifestyle (abstinent 
on a long term and persistent basis) and agree to remain abstinent 
● 
Use a male condom plus partner use of a contraceptive method with a failure rate of <1% 
per year as described in table below when having penile-vaginal intercourse with a woman 
of childbearing potential who is not currently pregnant. 
Note: Men with a pregnant or breastfeeding partner must agree to remain abstinent from 
penile-vaginal intercourse or use a male condom during each episode of penile penetration. 
 
 
 

EAU RF protocol  2018-02 
                                                                                                                                                          
Adjuvant Pemigatinib in surgically treated high-risk UC  
 
 
 
 
 
 
 
 
Final version 2.1, October 4th, 2021 
 
 
CONFIDENTIAL INFORMATION 
      Page 36 of 43 
 
 
Female Participants: 
Female participants of childbearing potential are eligible to participate if they agree to use a highly 
effective method of contraception consistently and correctly for 30 days prior to administration of 
study treatment, continue contraception during the study treatment period and for 150 days after the 
last study treatment (120 days to eliminate study treatment and 30 days menstruation cycles).  
 
Table:  Highly Effective Contraception Methods 
 
Highly Effective Contraceptive Methods That Are User Dependent a  
Failure rate of < 1% per year when used consistently and correctly. 
● Combined (estrogen- and progestogen- containing ) hormonal contraception b, c 
○ Oral  
○ Intravaginal  
○ Transdermal  
○ Injectable 
● Progestogen-only hormonal contraception b, c 
○ Oral  
○ Injectable  
Highly Effective Methods That Have Low User Dependency  
Failure rate of <1% per year when used consistently and correctly. 
● Progestogen- only contraceptive implant b, c  
● Intrauterine hormone-releasing system b  
● Intrauterine device 
● Bilateral tubal occlusion 
● Vasectomized partner  
A vasectomized partner is a highly effective contraception method provided that the partner is the sole 
male sexual partner of the WOCBP and the absence of sperm has been confirmed.  If not, an additional 
highly effective method of contraception should be used.  
● Sexual abstinence  
Sexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated with the study treatment.  The 
reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the 
preferred and usual lifestyle of the participant.)  
Notes:  
Use should be consistent with local regulations regarding the use of contraceptive methods for 
participants of clinical studies.  
 
a) Typical use failure rates are lower than perfect-use failure rates (i.e. when used consistently and 
correctly).  
b) Acceptable hormonal contraceptives are limited to those which inhibit ovulation.  
c) Hormonal contraception may be susceptible to interaction with Pemigatinib, which may reduce the 
efficacy of the contraception method. 
 
 
 
 
 

EAU RF protocol  2018-02 
                                                                                                                                                          
Adjuvant Pemigatinib in surgically treated high-risk UC  
 
 
 
 
 
 
 
 
Final version 2.1, October 4th, 2021 
 
 
CONFIDENTIAL INFORMATION 
      Page 37 of 43 
 
 
Pregnancy Testing 
 
WOCBP should only be included after a negative highly sensitive urine or serum pregnancy test.  
 
Following initiation of treatment, pregnancy testing will be performed whenever an expected 
menstrual cycle is missed or when pregnancy is otherwise suspected, after the last dose of study 
treatment, and as required locally. 
 
 
 
 

EAU RF protocol  2018-02 
                                                                                                                                                          
Adjuvant Pemigatinib in surgically treated high-risk UC  
 
 
 
 
 
 
 
 
Final version 2.1, October 4th, 2021 
 
 
CONFIDENTIAL INFORMATION 
      Page 38 of 43 
 
 
Appendix 2 Common Terminology Criteria for Adverse Events v 4.0 (CTCAE) 
 
The descriptions and grading scales found in the revised National Cancer Institute Common 
Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for adverse event 
reporting.  
 
http://www.hrc.govt.nz/sites/default/files/CTCAE%20manual%20-%20DMCC.pdf 
 
 
 
 
 

EAU RF protocol  2018-02 
                                                                                                                                                          
Adjuvant Pemigatinib in surgically treated high-risk UC  
 
 
 
 
 
 
 
 
Final version 2.1, October 4th, 2021 
 
 
CONFIDENTIAL INFORMATION 
      Page 39 of 43 
 
 
Appendix 3 Investigator Protocol Signature Sheet 
 
Investigator Signature: 
 
I have read and agree to the ‘Open-label, single-arm, Phase II study, evaluating safety and efficacy 
of Pemigatinib as adjuvant therapy for molecularly-selected, high-risk patients with urothelial 
carcinoma who have received radical surgery.  
A European Association of Urology Research Foundation Phase II Clinical Trial.  
EAU RF number: 2018-02. Final Version 2.0 dated 29 June 2021. 
 
I agree to conduct this study in accordance with the protocol and in accordance with the Declaration 
of Helsinki and (inter)national regulations (as applicable) and to appropriately direct and assist the 
staff under my control, who will be involved in the study. 
 
 
NAME: 
 
 
 
 
TITLE: 
INVESTIGATOR: 
SIGNATURE: 
 
 
 
DATE: 
 
PLACE: 
 
 
 
Full investigational site contact details, including telephone numbers, will be documented in the 
Trial Master File. 
 
 
 
Principal Investigator: 
 
 
NAME: 
Prof. Andrea Necchi 
 
 
 
 
SIGNATURE: 
 
 
 
DATE: 
 
MILANO, ITALY 
 
 
 
Sponsors Medical Expert and Epidemiologist: 
 
 
NAME: 
Dr. Wim PJ Witjes 
 
 
 
 
SIGNATURE: 
 
 
 
 
DATE: 
 
ARNHEM, THE NETHERLANDS 
 

EAU RF protocol  2018-02 
                                                                                                                                                          
Adjuvant Pemigatinib in surgically treated high-risk UC  
 
 
 
 
 
 
 
 
Final version 2.1, October 4th, 2021 
 
 
CONFIDENTIAL INFORMATION 
      Page 40 of 43 
 
 
 
Appendix 4 WHO Performance Score & NYHA Classification of Heart Failure 
 
WHO Performance Score 
The WHO score (published by Oken et al in 1982 [25], also called the ECOG or Zubrod score (after 
C. Gordon Zubrod), runs from 0 to 5, with 0 denoting perfect health and 5 death: 
0. 
Asymptomatic  
1. 
Symptomatic but completely ambulatory  
2. 
Symptomatic, <50% in bed during the day  
3. 
Symptomatic, >50% in bed, but not bedbound  
4. 
Bedbound  
5. 
Death 
Classes of Heart Failure 
Doctors usually classify patients' heart failure according to the severity of their symptoms. The table 
below describes the most commonly used classification system, the New York Heart Association 
Functional Classification1 (NYHA). It places patients in one of four categories based on how much 
they are limited during physical activity. 
Class Patient Symptoms 
I 
No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, 
palpitation, dyspnea (shortness of breath). 
II 
Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in 
fatigue, palpitation, dyspnea (shortness of breath). 
III 
Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes 
fatigue, palpitation, or dyspnea. 
IV 
Unable to carry on any physical activity without discomfort. Symptoms of heart failure at 
rest. If any physical activity is undertaken, discomfort increases. 
 
 
1 Adapted from Dolgin M, Association NYH, Fox AC, Gorlin R, Levin RI, New York Heart 
Association. Criteria Committee. Nomenclature and criteria for diagnosis of diseases of the heart 
and great vessels. 9th ed. Boston, MA: Lippincott Williams and Wilkins; March 1, 1994. 
Original source: Criteria Committee, New York Heart Association , Inc. Diseases of the Heart and 
Blood Vessels. Nomenclature and Criteria for diagnosis, 6th edition Boston, Little, Brown and Co. 
1964, p 114. 
 

EAU RF protocol  2018-02 
                                                                                                                                                          
Adjuvant Pemigatinib in surgically treated high-risk UC  
 
 
 
 
 
 
 
 
Final version 2.1, October 4th, 2021 
 
 
CONFIDENTIAL INFORMATION 
      Page 41 of 43 
 
 
Appendix 5 CYP3A Inhibitors and Inducers 
 
Source: University of Washington School of Pharmaceutics: Drug Interaction Database Program. 
2002. http://www.druginteractioninfo.org. Accessed May 2015. Highlighted row indicates recent 
additions to the lists at the time the database search was performed. 
 
 
 
 
 
 
 
 
 

EAU RF protocol  2018-02 
                                                                                                                                                          
Adjuvant Pemigatinib in surgically treated high-risk UC  
 
 
 
 
 
 
 
 
Final version 2.1, October 4th, 2021 
 
 
CONFIDENTIAL INFORMATION 
      Page 42 of 43 
 
 
 
Appendix 6 Flowchart and Laboratory Evaluations. 
 
 
 
 
 
 
 
 
Pre-
sur-
gery 
Sur-
gery 
Screeni
ng 
Treatment period 12 months 
 
Follow up after treatment 12 
months 
 
 
 
Week 0 
up to 
week 13 
after 
surgery 
First 3 weeks after start of 
treatment 
Q 3 
weeks* 
 
 
End of 
Treatme
nt (EOT) 
Safety 
Disease 
status 
Survival 
status 
Day 1 
enrollme
nt   
Day 8 (± 
3 days) 
Day 15 
(± 3 
days) 
Day 21 
(± 3 
days), 
etc 
EOT + 
30-35 
days 
Every 
12 
weeks 
Every 12 
weeks 
Inf.Consent  
X 
 
X 
 
 
 
 
 
 
 
 
Selection criteria 
X 
 
X 
X 
 
 
 
 
 
 
 
Tumor Tissue for 
genomic profiling 
 
 
X 
 
 
 
 
 
 
 
 
Demographics & 
Med. History 
 
 
X 
 
 
 
 
 
 
 
 
Phys. Exam. & 
NYHA status 
 
 
X 
 
 
 
 
 
 
 
 
WHO PS 
 
 
X 
X 
 
 
X 
X 
 
X 
 
ECG 
 
 
X 
 
 
 
X q12 
wks 
Prev. 
Abn. 
Prev. 
Abn. 
 
 
Hematology & 
Biochemistry 
 
 
X 
Repeated 
only if 
done > 14 
days prior 
to day 1 
X 
X 
X q3 
wks* 
 
 
Prev. 
Abn. 
 
 
Prev. 
Abn. 
 
 
Urine / Serum 
Pregnancy test 
(females of 
childbearing 
potential) 
 
 
X 
X 
Only in 
case of 
susp. 
preg-
nancy 
Only in 
case of 
susp. 
preg-
nancy 
Only in 
case of 
susp. 
preg-
nancy 
Only in 
case of 
susp. 
preg-
nancy 
Only in 
case of 
susp. 
preg-
nancy 
Only in 
case of 
susp. 
preg-
nancy 
 
Urinalysis, 
Coagulation, Lipid 
and Endocrine 
Panels 
 
 
X 
 
 
 
 
X *** 
 
Prev. 
Abn. 
 
Prev. 
Abn. 
 
 
CT / MRI 
chest/abdomen/pelvi
s Q 12 weeks** 
 
 
X 
 
 
 
 
X q12 
wks 
 
 
 
X 
 
Ophthalmological 
investigations 
every12 weeks 
 
 
X 
 
 
 
 
X q12 
wks 
 
Prev. 
Abn. 
 
 
 
Study drug 
dispensing and 
accountability 
 
 
 
X 
 
 
X 
X 
 
 
 
Concomitant 
medication 
 
 
X 
X 
X 
X 
X 
X 
X 
 
 
Adverse events 
(CTCAE v4.0) 
 
 
 
 
X 
X 
X 
X 
X 
X only 
study or 
drug 
related 
SAEs 
X only 
study or 
drug related 
SAEs 
 Survival data  
 
 
 
 
 
 
 
 
 
 
X 
Prev. Abn.: Only in case of abnormalities at previous, latest test or examination. 
* Timing of subsequent visits and laboratory examinations can be prolonged to max. 9 weeks intervals if no problems exist during the first 12 weeks of therapy.   
** CT / MRI every 12 weeks +/- 1 week. At disease relapse or progression, a biopsy and subsequent genomic evaluation is recommended. 
*** Urinalysis, Coagulation panel, Lipid panel and Endocrine panel (next page): repeat at 3 weeks and only in case of (persistent) abnormalities repeat q3 weekly; 
EOT and Safety EOT + 30 days only in case of previous, latest test abnormalities.     

 
EAU RF protocol  2018-02 
                                                                                                                                                          
Adjuvant Pemigatinib in surgically treated high-risk UC  
 
 
 
 
 
 
 
 
 
 
Final version 2.0, June 29th, 2021 
 
 
                                                                                                   CONFIDENTIAL INFORMATION 
                                                                                                                                                                                                Page 43 of 43 
 
Laboratory test to be performed in the local laboratory at each hospital. Other than hematology and chemistry lab tests: Hepatitis screening only at screening, if 
not done already before radical surgery.  
Urinalysis, Coagulation panel, Lipid panel and Endocrine panel: repeat at 3 weeks and only in case of (persistent) abnormalities repeat q3 weekly; EOT and 
Safety EOT + 30 days only in case of previous, latest test abnormalities.   
 
Hematology 
Chemistry 
Urinalysis 
Other 
Hematocrit 
Total protein 
Occult Blood 
Hepatitis serology 
Hemoglobin 
Albumin 
Glucose 
 
Platelet count 
Alkaline phosphatase 
Protein 
 
WBC (total and differential) 
Alanine aminotransferase (ALT) 
PH and Specific gravity  
 
Red Blood Cell Count 
Aspartate aminotransferase (AST) 
Bilirubin 
 
Absolute Neutrophil Count 
Lactate dehydrogenase (LDH) 
Urobilinogen 
COAGULATION PANEL 
Absolute Lymphocyte Count 
Total Bilirubin 
Ketones 
PT (INR) 
 
Direct Bilirubin (If total bilirubin is 
elevated above the upper limit of 
normal) 
Leukocytes 
Activated Partial Thromboplastine Time 
(aPTT) 
 
Uric Acid 
Nitrite 
 
 
Creatinine / Creatinine clearance 
according to Cockroft-Gault formula. 
 
LIPID PANEL 
 
Blood Urea Nitrogen 
Urine pregnancy test and/or serum 
β-human chorionic gonadotropin† 
(β-hCG) † 
 Total cholesterol 
 
Calcium 
 
 Triglycerides 
 
Chloride 
 
 Low-density lipoprotein 
 
Glucose 
 
 High-density lipoprotein 
 
Phosphate 
 
 
 
Potassium   
 
ENDOCRINE PANEL 
 
Sodium 
 
Parathyroid hormone (PTH) 
 
Vitamin D (25-hydroxyvitamin D and 
1,25-dihidroxyvitamin D) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
† Perform on women of childbearing potential only. If urine pregnancy results cannot be confirmed as negative, a serum pregnancy test will be required.